Original Article
Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy
N Engl J Med 2008; 358:2433-2446June 5, 2008
- Abstract
Background
Diabetic nephropathy is the leading cause of end-stage renal disease in developed countries. We evaluated the renoprotective effects of dual blockade of the renin−angiotensin−aldosterone system by adding treatment with aliskiren, an oral direct renin inhibitor, to treatment with the maximal recommended dose of losartan (100 mg daily) and optimal antihypertensive therapy in patients who had hypertension and type 2 diabetes with nephropathy.
Methods
We enrolled 599 patients in this multinational, randomized, double-blind study. After a 3-month, open-label, run-in period during which patients received 100 mg of losartan daily, patients were randomly assigned to receive 6 months of treatment with aliskiren (150 mg daily for 3 months, followed by an increase in dosage to 300 mg daily for another 3 months) or placebo, in addition to losartan. The primary outcome was a reduction in the ratio of albumin to creatinine, as measured in an early-morning urine sample, at 6 months.
Results
The baseline characteristics of the two groups were similar. Treatment with 300 mg of aliskiren daily, as compared with placebo, reduced the mean urinary albumin-to-creatinine ratio by 20% (95% confidence interval, 9 to 30; P<0.001), with a reduction of 50% or more in 24.7% of the patients who received aliskiren as compared with 12.5% of those who received placebo (P<0.001). A small difference in blood pressure was seen between the treatment groups by the end of the study period (systolic, 2 mm Hg lower [P=0.07] and diastolic, 1 mm Hg lower [P=0.08] in the aliskiren group). The total numbers of adverse and serious adverse events were similar in the groups.
Conclusions
Aliskiren may have renoprotective effects that are independent of its blood-pressure−lowering effect in patients with hypertension, type 2 diabetes, and nephropathy who are receiving the recommended renoprotective treatment. (ClinicalTrials.gov number, NCT00097955.)
Media in This Article
Figure 1
Numbers of Patients Who Were Screened for the Study, Who Underwent Randomization, and Who Completed the Study.Figure 2
Changes from Baseline in the Urinary Albumin-to-Creatinine Ratio, Urinary Albumin Excretion Rate, and Blood Pressure According to Study Group.Article Activity
- Article
The pathogenesis of diabetic nephropathy is multifactorial, and the renin−angiotensin−aldosterone system plays an important role.1,2 Persistent proteinuria is the hallmark of diabetic nephropathy, a condition that is characterized by a progressive rise in blood pressure, a declining glomerular filtration rate, and a high risk of fatal or nonfatal cardiovascular events. The degree of proteinuria is closely associated with the rates of renal and cardiovascular events.3,4 Furthermore, a reduction in proteinuria is associated with a slowing of both the decline in the glomerular filtration rate5 and the progression to end-stage renal disease.6 In addition, decreasing proteinuria is associated with improved cardiovascular outcomes in patients with diabetic nephropathy7 and arterial hypertension.8 As a result, a reduction in proteinuria has been widely used as a surrogate end point for renoprotection.
During the past two decades, the outlook for patients with diabetes who have microalbuminuria or macroalbuminuria has improved, probably owing to early aggressive lowering of blood pressure and blocking of the renin−angiotensin−aldosterone system.3,4,9-12 However, there is still a large, unmet need to develop strategies for the prevention of diabetic nephropathy and its progression to end-stage renal disease. Diabetic nephropathy remains the leading cause of end-stage renal disease in the developed world.
The aim of this trial was to evaluate the potential renoprotective capacity of direct renin inhibition with aliskiren in patients with hypertension, type 2 diabetes, and proteinuria who were already receiving the maximal recommended renoprotective treatment with losartan (100 mg daily) and optimal treatment for hypertension. In addition, the safety of dual blockade of the renin−angiotensin−aldosterone system was monitored and recorded.
Methods
Patients
We enrolled patients with hypertension who were 18 to 85 years of age and who had type 2 diabetes and nephropathy (defined by an early-morning urinary albumin-to-creatinine ratio of >300 mg per gram, or >200 mg per gram in patients receiving therapy targeted at blockade of the renin−angiotensin−aldosterone system). The criteria for exclusion were known nondiabetic kidney disease, a urinary albumin-to-creatinine ratio of more than 3500 mg per gram, an estimated glomerular filtration rate of less than 30 ml per minute per 1.73 m2 of body-surface area,13 chronic urinary-tract infection, a serum potassium level greater than 5.1 mmol per liter at the time of randomization, severe hypertension, or major cardiovascular disease within the previous 6 months.
Study Design
In a randomized, double-blind, placebo-controlled study that was conducted in 15 countries and 150 centers worldwide, we evaluated the possible renoprotective effect of aliskiren in 599 patients with hypertension, type 2 diabetes, and nephropathy. We screened 1892 eligible patients at an enrollment visit (Figure 1Figure 1
Numbers of Patients Who Were Screened for the Study, Who Underwent Randomization, and Who Completed the Study.). A total of 805 patients entered a 3-month open-label period during which all drugs that the patients had been taking that block the renin−angiotensin−aldosterone system were discontinued, except for beta-blockers, and treatment was initiated with the maximal recommended renoprotective dose of losartan (100 mg daily) plus additional antihypertensive therapy that was aimed at achieving an optimal target blood pressure (i.e., <130/80 mm Hg). During the 3-month open-label treatment period, 206 patients were excluded, leaving 599 patients who underwent randomization and were followed for a median of 6 months (Figure 1). Patients were randomly assigned to receive 150 mg of aliskiren once daily for 3 months, followed by 300 mg of aliskiren daily for another 3-month period, or matching placebo once daily for 6 months. The randomization list was generated by a validated system that automated the random assignment of treatment groups to randomization numbers. The study protocol was in accordance with the Declaration of Helsinki (2002) and was approved by local and central review boards. All patients provided written informed consent. The study was overseen by a steering committee that included nonvoting members from the sponsor, Novartis. The steering committee oversaw the design of the study, the conduct of the trial, and the management and analysis of all data. The sponsor was also involved in the design of the study and in the collection and analysis of the data. All authors had access to all study data and vouch for the accuracy and completeness of the data reported.Procedures, Measurements, and Outcome
The patients were examined 13, 12, 8, 4, and 2 weeks before randomization; at the time of randomization; and 1, 4, 8, 11, 12, 16, and 24 weeks after randomization. To account for the delay in obtaining results of laboratory tests, the baseline urinary albumin-to-creatinine ratio, which was based on the median values in three early-morning urine collections, was calculated 2 weeks before randomization. Blood pressure and pulse, adverse events, concomitant medications, and adherence to medication regimens were assessed at each visit. Three early-morning spot urine specimens were collected on 3 sequential days 13 weeks and 2 weeks before randomization and 4, 8, 12, 16, and 24 weeks after randomization. Three overnight urine specimens were obtained on 3 sequential nights 2 weeks before randomization (baseline) and 12 and 24 weeks after randomization. All assessments of urine and blood were performed by the same company (CRL.Medinet) in a central laboratory in Europe or the United States. The urinary albumin concentration was determined by immunoturbidimetry,14 and the serum creatinine concentration was determined by means of the Jaffe reaction (with the use of a Roche kit).15 The Modification of Diet in Renal Disease (or MDRD) formula was used to estimate the glomerular filtration rate.13 Glycated hemoglobin was measured by means of high-performance liquid chromatography (Bio-Rad).16 All the other laboratory variables were also measured centrally with the use of conventional laboratory techniques.
Blood pressure, measured while the patient was seated, was assessed after at least 5 minutes of rest with the use of standard mercury sphygmomanometers and an appropriately sized cuff. Three measurements were obtained, 2 minutes apart at each time point, and the average of the three was used for the calculation of the 24-hour trough level (i.e., the level 24 hours after administration of the drug). The target blood pressure during the open-label and double-blind periods was less than 130/80 mm Hg for both groups. Consequently, further adjustments, as needed, in the dosing of blood-pressure–lowering medication were recommended after random assignment to bring the patient's blood pressure closer to the target. All classes of blood-pressure−lowering drugs were allowed, except for drugs that block the renin−angiotensin−aldosterone system. Patients continued to receive their usual care for diabetes and cardiovascular protection (Table 1Table 1
Baseline Characteristics of the Randomized Population.). No restriction on dietary salt or protein was mandated. The primary efficacy measure was the percentage reduction in the early-morning urinary albumin-to-creatinine ratio from baseline to the end of the study (24 weeks) among patients who received aliskiren, as compared with patients who received placebo.Statistical Analysis
Our target sample size for patients completing the study was approximately 396 patients (198 per treatment group). Assuming a dropout rate of 20%, we planned to randomly assign 496 patients. This sample size would have provided 90% power to detect, at a two-sided level of significance of 0.05, a treatment difference of 18% in the primary end point — the change in the urinary albumin-to-creatinine ratio from baseline to week 24 — between the group that received aliskiren and the group that received placebo (assuming a standard deviation of 55%). However, 599 patients were enrolled, mainly as a result of a long screening and run-in period, an increased rate of enrollment at the end of the recruitment phase, and a decreased rate of screening failure toward the end of the enrollment phase. With 599 patients enrolled, and with the same assumptions as stated above, the power was approximately 94%.
Changes in the log-transformed urinary albumin-to-creatinine ratio from baseline (2 weeks before randomization) to weeks 4, 12, and 16 and to week 24 (end point) were assessed for the intention-to-treat population with the use of an analysis of covariance (ANCOVA) model, with treatment and region as factors and baseline log-transformed albumin-to-creatinine ratio as the covariate. To adjust for differences in the change in systolic blood pressure from baseline, the log-transformed urinary albumin-to-creatinine ratio was also analyzed with the use of an ANCOVA model in which treatment and region were variables, with the baseline urinary albumin-to-creatinine ratio and the change from baseline in systolic blood pressure as covariates. For patients with missing albumin-to-creatinine ratio values for week 24 (13% and 9.7% in the aliskiren and placebo groups, respectively), the last post-baseline urinary albumin-to-creatinine ratio was carried forward for the week-24 end-point analysis. Patients who had an adverse event or an abnormal value on a laboratory test but who remained in the study were followed for its duration and included in the analysis of efficacy at 24 weeks. Patients who withdrew from the study were monitored for adverse events or abnormal values on laboratory tests for the duration of the study. Treatment comparisons between the patients who received aliskiren and those who received placebo were performed with the use of a two-sided test with a significance level of 0.05. Least-squares mean differences between the groups (aliskiren vs. placebo) for the change from baseline in the urinary albumin-to-creatinine ratio (and associated 95% confidence intervals) were back-transformed to provide aliskiren-to-placebo ratios. In addition, a mixed-effects model with the use of the appropriate procedure of the SAS package (SAS PROC MIXED) was implemented for the primary end point. The model included study group, visit, and the interaction term for these two factors, as well as region and baseline urinary albumin-to-creatinine ratio, as fixed effects and visits as repeated measurements. A common correlation structure for albumin-to-creatinine ratio was assumed for each patient.
Changes from baseline in the urinary albumin excretion rate, blood pressure, and estimated glomerular filtration rate were analyzed with the use of an ANCOVA model, with treatment, region, and baseline proteinuria classification as factors and respective baseline values for the urinary albumin excretion rate, blood pressure, and glomerular filtration rate as covariates. Analyses of the urinary albumin excretion rate and the estimated glomerular filtration rate were performed with the use of log-transformed data. Correlations between changes from baseline in blood pressure and changes from baseline in the urinary albumin-to-creatinine ratio were assessed by linear regression analysis. All statistical analyses were performed with SAS software, version 8.2 or higher (SAS Institute).
Results
Characteristics of the Patients
Baseline demographic, clinical, and biochemical characteristics and the number of patients who were receiving glucose-lowering and lipid-lowering therapies and aspirin (≤325 mg daily) were balanced between the two groups, except that the patients in the placebo group were slightly older (P=0.009) (Table 1). The mean glycated hemoglobin values remained unchanged, at 8.0%, in the aliskiren group and rose to 8.1% in the placebo group, and the numbers of severe hypoglycemic episodes were zero and one, respectively. Additional blood-pressure−lowering drugs that were taken by patients in the two groups are shown in Table 2Table 2
Concomitant Antihypertensive Therapies Received at Baseline and during the Double-Blind Period among Patients with Type 2 Diabetes and Nephropathy..Primary and Secondary Outcomes
By the end of the study period, treatment with aliskiren (150 mg daily for 3 months, followed by 300 mg daily for another 3 months) had reduced the mean urinary albumin-to-creatinine ratio by 20%, as compared with placebo (95% confidence interval [CI], 9 to 30; P<0.001) (Figure 2AFigure 2
Changes from Baseline in the Urinary Albumin-to-Creatinine Ratio, Urinary Albumin Excretion Rate, and Blood Pressure According to Study Group.). The mixed-effects model yielded an identical reduction of 20% in the mean urinary albumin-to-creatinine ratio (95% CI, 11 to 29; P<0.001). After adjustment for the change from baseline in systolic blood pressure, the reduction was 18% (95% CI, 7 to 28; P=0.002). By week 12, 150 mg of aliskiren daily, as compared with placebo, had decreased the urinary albumin-to-creatinine ratio by 11% (95% CI, 2 to 20; P=0.02). At week 24, the overnight urinary albumin excretion rate showed a similar pattern, with a reduction of 18% in the aliskiren group (95% CI, 5 to 30; P=0.009 for the comparison with the placebo group) (Figure 2B). After adjustment for the change from baseline in systolic blood pressure, the reduction was 17% (95% CI, 4 to 29; P=0.02). Mean blood pressure, measured while the patient was seated, was nearly identical at baseline in the two groups. By the end of the study period (week 24), the mean blood pressure in the aliskiren group was 2/1 mm Hg lower than that in the placebo group (P=0.07 for systolic pressure, P=0.08 for diastolic pressure) (Figure 2C).A reduction of 50% or more in albuminuria was seen in 24.7% of the patients who received aliskiren, as compared with 12.5% of the patients who received placebo (P<0.001). A comparison of baseline characteristics between patients who had a heightened response (a reduction of 50% or more in albuminuria) and those who had a normal response (a reduction of less than 50% in albuminuria) did not reveal any significant differences.
There were no significant differences in the response to aliskiren among subgroups of patients (Figure 3Figure 3
Relative Change from Baseline in the Urinary Albumin-to-Creatinine Ratio after Treatment with Aliskiren as Compared with Placebo in Subgroups of Patients.). Even though aliskiren appeared to have a beneficial effect or trend in all subgroups, the effect was not always significant. The mean rate of decline in the estimated glomerular filtration rate during the 24-week study period was 2.4 ml per minute per 1.73 m2 (95% CI, 1.1 to 3.7) in the aliskiren group and 3.8 ml per minute per 1.73 m2 (95% CI, 2.5 to 5.1) in the placebo group (P=0.07).Adverse Events
There was no difference in the overall incidence of adverse events between the aliskiren group and the placebo group (66.8% and 67.1%, respectively) (Table 3Table 3
Serious Adverse Events, Adverse Events, and Prespecified Abnormal Laboratory Values during Double-Blind Treatment (Safety Population).). The rate of serious adverse events was also similar (9.0% and 9.4%, respectively), as was the percentage of patients who withdrew from the study owing to adverse events (5.6% and 6.4%, respectively). There were no deaths in the aliskiren group and two deaths in the placebo group. Hyperkalemia was reported in 5.0% of the patients in the aliskiren group and in 5.7% of the patients in the placebo group. A total of 14 patients (4.7%) in the aliskiren group had at least one value for the serum potassium level that was 6.0 mmol per liter or more, as compared with 5 patients (1.7%) in the placebo group (P=0.06). A total of 9 of the 14 aliskiren-treated patients had had a serum potassium level of 5.1 mmol per liter or more at baseline, a level that should have led to the exclusion of the patients from the study, according to the exclusion criteria described earlier. Of these 9 patients, 3 were excluded from the study when the laboratory value became available. One of the remaining 11 patients withdrew from the study because a subsequent laboratory test showed a serum potassium level of 6.3 mmol per liter. The mean (±SD) serum creatinine level in the aliskiren group at baseline was 1.4±0.6 mg per deciliter (123.76±53.04 μmol per liter). Only half of the patients in the two study groups who had at least one value for serum potassium that was 6.0 mmol per liter or more (a total of 16 patients) received a diuretic. None of the five patients in the placebo group had a serum potassium level of 5.1 mmol per liter or more at baseline, and the mean value for these five patients was 4.7±0.2 mmol per liter at baseline. The hyperkalemia was transient, and none of the five patients stopped taking the study medication.Discussion
The present trial shows that treatment with 300 mg of aliskiren daily reduces albuminuria in patients with hypertension, type 2 diabetes, and proteinuria who are receiving the recommended maximal renoprotective treatment with losartan and optimal antihypertensive therapy. Furthermore, a 50% reduction in albuminuria was seen twice as often in the group that received 300 mg of aliskiren daily as in the group that received placebo. The benefits of aliskiren appear to be independent of the systemic blood pressure; average trough systolic and diastolic blood pressures during the study were only marginally lower in the aliskiren group than in the placebo group, and an analysis that adjusted for these small differences confirmed the renoprotective effect of aliskiren. In addition, the decline in kidney function tended to be smaller among the patients who received aliskiren than among those who received placebo.
The benefit of blocking the renin−angiotensin−aldosterone system in patients with diabetes who are at risk for end-stage renal disease is now well established.3,4,10-12 However, most studies to date also show that renal disease progresses in many patients despite treatment with angiotensin-converting−enzyme (ACE) inhibitors or angiotensin II−receptor blockers.3,4,10-12 Consequently, alternatives that optimize the blockade of the renin−angiotensin−aldosterone system are being explored in the hope that a more complete blockade will lead to a better therapeutic outcome.17 New renoprotective strategies include dual blockade of the renin−angiotensin−aldosterone system with the use of ACE inhibitors and angiotensin II–receptor blockers, very high doses of angiotensin II−receptor blockers,18-20 aldosterone blockade,21,22 and, as in the present study, direct renin inhibition.
Aliskiren, the renin inhibitor used in our study, has a 40-hour half-life and reduces both blood pressure and plasma renin activity. It is well established that a dose of 300 mg of aliskiren is optimal for the reduction of blood pressure.23 Further information concerning the development of oral renin inhibitors and their pharmacokinetic and pharmacodynamic properties, with a focus on aliskiren, is available in a recent review.24
In a study reported in 2000 that involved patients with type 2 diabetes, hypertension, and microalbuminuria, Mogensen et al.25 showed that treatment with a combination of submaximal doses of candesartan and lisinopril was more effective in reducing blood pressure (reductions in systolic pressure of approximately 10 mm Hg and in diastolic pressure of approximately 6 mm Hg) than therapy with only one agent; however, the effectiveness of the combined therapy in reducing albuminuria was not firmly established. Since then, numerous small studies, often using submaximal doses of ACE inhibitors in patients with diabetic nephropathy, have shown a significant reduction in blood pressure and albuminuria with this treatment strategy.26 In contrast, a large, randomized, controlled trial involving patients with type 2 diabetes, hypertension, and albuminuria who received the maximal recommended doses of ramipril and irbesartan failed to show a significant effect of combination therapy, as compared with monotherapy, on albuminuria,27 despite a significant reduction in systemic blood pressure. However, this study may have been underpowered, owing to a more marked variability in the urinary albumin excretion rate than anticipated. Our study was larger and adequately powered, and the results clearly support a specific renoprotective effect of aliskiren — namely, a beneficial effect on kidney function beyond the effect on hypertension. However, we cannot completely rule out the possibility that changes in antihypertensive medications after randomization might have confounded the results of our study.
Glomerular proteinuria is determined by four factors: the mean transcapillary hydraulic-pressure difference, the glomerular surface area, and the size selectivity and charge selectivity of the glomerular filter. In diabetic nephropathy several of these variables are abnormal, and blockade of the renin−angiotensin−aldosterone system has been shown to normalize directly measured or estimated glomerular hydraulic pressure,28-30 to reduce the shunt-like defects in the membrane, at least in part,31,32 and to restore the charge-selectivity properties of the glomerular membrane.33
In our study, the estimated glomerular filtration rate was nearly identical in the two groups at baseline, whereas the decline in the glomerular filtration rate tended to be smaller among the patients who were treated with aliskiren for 6 months than among the patients who were given placebo. Long-term studies (more than 2 years' duration) must be conducted to elucidate whether the beneficial effect on the kidney that is seen in the short term is sustained.
Previous studies with antihypertensive drugs have usually shown an initial drop in the glomerular filtration rate that is steeper than the sustained decline.11,34 Recently, a study of healthy people on a low-sodium diet has shown that renal vasodilatation with aliskiren far exceeds that seen with ACE inhibitors and angiotensin II−receptor blockers.35 These results indicate that aliskiren may provide greater and thus more effective blockade of the renin system in the kidney. Since the renin system is enhanced in patients with diabetes, as compared with controls,36 a more pronounced difference in renal vasodilatation may be expected during aliskiren therapy.
During the course of the trial, the average difference in blood pressure was only 2 mm Hg systolic and 1 mm Hg diastolic in favor of the dual blockade of the renin−angiotensin−aldosterone system. Studies of the same treatment approach (300 mg of aliskiren combined with 320 mg of valsartan37 or 10 mg of ramipril38) in patients with essential hypertension have shown at least a doubling of the difference in blood pressure in the combination-therapy groups as compared with the monotherapy groups. A likely explanation for this finding is that the patients in these two trials had a much higher average baseline blood pressure than the patients in our study, whose baseline blood pressure was well controlled. Even though many of the patients in both of our study groups received three or more antihypertensive agents, our systolic blood-pressure goal of 130 mm Hg was reached in less than half the patients, whereas our diastolic blood-pressure goal of 80 mm Hg was reached in the majority of patients in both groups. Previous studies among patients with diabetic nephropathy have also shown that ideal control of systolic blood pressure is very difficult to attain in patients with diabetes, probably owing to the presence of diabetic macroangiopathy.2-4,11
It is possible that aliskiren also differs from ACE inhibitors or angiotensin II−receptor blockers in other ways that might explain these results. In 2002, Nguyen et al.39 discovered a (pro)renin receptor that was detected in the brain, heart, liver, and kidney. Prorenin, when bound to the (pro)renin receptor, displayed enzymatic activity and activation of intracellular signaling pathways without proteolytic removal of the prosegment. Recent studies in animals with diabetes40,41 and in in vitro conditions with high glucose42 have shown that aliskiren reduces the number of (pro)renin receptors in the kidney, mitigates profibrotic activity in the kidney, and nearly abolishes the apoptotic effects on cultured podocytes. Furthermore, data from transgenic (mRen-2)27 rats with diabetes suggest that aliskiren has a greater renoprotective capacity than ACE inhibitors.43 These findings are consistent with the observation that an elevated plasma prorenin level is associated with the development of diabetic nephropathy.1
The combination therapy consisting of the maximal recommended doses of aliskiren and losartan had similar tolerability to therapy with placebo and losartan, consistent with findings in an earlier study of the combination of aliskiren and valsartan.37 Hyperkalemia was reported in 5.0% of the patients in the aliskiren group and in 5.7% of the patients in the placebo group. The number of patients with a serum potassium level of 6.0 mmol per liter or more was higher with the combined drugs than with placebo, although the occurrence of such cases, after adjustment for the nine patients who were mistakenly enrolled in the trial, was low.
In conclusion, aliskiren appears to have a renoprotective effect that is independent of its blood-pressure–lowering effect in patients with type 2 diabetes who are receiving the maximal recommended renoprotective treatment and optimal antihypertensive therapy.
Supported by Novartis Pharma.
Dr. Parving reports serving as a consultant for and receiving lecture fees from Novartis, Merck, Pfizer, and Sanofi-Aventis, having equity interest in Merck and Novo Nordisk, and receiving grant support from Novartis, AstraZeneca, and Sanofi-Aventis; Dr. Persson, having equity interest in Novo Nordisk; Dr. E. Lewis, receiving grant support from Keryx Biopharmaceuticals; Dr. J.B. Lewis, serving as a consultant to Merck and Novartis and receiving grant support from Keryx Biopharmaceuticals; and Dr. Hollenberg, receiving grant support from Novartis and Merck.
No other potential conflict of interest relevant to this article was reported.
We thank Karl Baer, Deborah L. Keefe, Vipin Arora, Jessica Ford, and Balthazar Mascaro for their substantial contributions.
Source Information
From the Department of Medical Endocrinology, Rigshospitalet, Copenhagen (H.-H.P.); the Faculty of Health Science, Aarhus University, Aarhus, Denmark (H.-H.P.); Steno Diabetes Center, Gentofte, Denmark (F.P.); Vanderbilt University School of Medicine, Nashville (J.B.L.); Rush University Medical Center, Chicago (E.J.L.); and Brigham and Women's Hospital and Harvard Medical School, Boston (N.K.H.).
Address reprint requests to Dr. Parving at the Department of Medical Endocrinology, Rigshospitalet, University Hospital of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen Ø, Denmark, or at hhparving@dadlnet.dk.
The investigators who participated in the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) study are listed in the Appendix.
Appendix
The following investigators participated in the study: Canada — M. Lebel, M. Agharazi (Quebec, QC); N. Muirhead, A. House, F. Rehman (London, ON); V. Pichette, M. LeBlanc, A. Bomardeaux, M. Houde (Montreal); G. Pylypchuk, A. Ahmed, J. Barton (Saskatoon, SK); S. Jolly (Kitchener, ON); Greece — K. Siamopoulos, I. Theodorou (Ioannina); E. Pagkalos, M. Gavra, A. Klitsas, K. Soulis (Thessaloniki); Portugal — M.J. Pais, L. Parreira, A. Ribeiro da Cunha, P. Carmo (Carnaxide); A. Gomes da Costa, S. Morgado da Silva (Lisbon); D. Carvalho, Â. Magalhães, A. Oliveira, J. Queirós (Porto); Turkey — A. Oguz, A. Erenmemisoglu, S. Seker, C. Muderrisoglu, E. Altinoglu, A. Erenmemisoglu, T. Ecder, H. Yazici (Istanbul); M. Arici, A. Erenmemisoglu, R. Yilmaz (Ankara); K. Dilek, A. Erenmemisoglu, S. Kahvecioglu, I. Akdag (Bursa); Denmark — H.-H. Parving, F. Persson, K. Schjødt, L. Tarnow (Gentofte); O.L. Svendsen, T. M. Christensen, M.-B. Tanderup Petersen, H. Perrild (Copenhagen); T. Almdal (Hvidovre); B. Thorsteinsson, O. Snorgård (Hillerød); H. Juhl, H. Hansen (Slagelse); J. Henriksen, B. Vind (Odense); O. Østergaard, E. Christiansen (Roskilde); France — G. Choukroun, N. El Esper, C. Presne (Amiens); J. Aldigier (Limoges); P. Bataille, D. Nour (Boulogne-sur-Mer); J.-P. Fauvel (Lyon); P. Zaoui, P. Malvezzi (Grenoble); J.-M. Halimi, P. Lecomte (Tours); G. Charpentier, B. Boucherie (Corbeil); Germany — T. Jung, N. Jung (Deggingen); J. Jordan, H. Mehling, P. Budziarek, S. Engeli (Berlin-Buch); H. Haller, J. Menne, S. Niescken, A. Herrmann, S. Hellweg, S. David, A. Deines (Hannover); R. Schmieder, B. Schmidt, T. Schäufele (Nuremberg); J. Simon (Fulda); E. Oerter (Wuerzburg); M. Rambausek, M. Schoemig, M. Stephan (Heilbronn); E. Austenat, C. Grothe, T. Lederer, B. Al-Masry (Berlin); G. Blume (Quedlinburg); C. Hohberg, R. Butzer, T. Forst, P. Musholt, B. Wilhelm (Mainz); A. Gruenerbel, M. Gruenerbel, C. Richter (Munich); Italy — A. Santoro, M. Federico, M. Mandreoli, L. Stalteri (Bologna); G. Remuzzi, P. Ruggenenti, E. Perticucci, S. Rota (Bergamo); L. Gesuaido, M. Ktena, E. Pallotta (Foggia); S. David, C. Grasselli (Parma); C. Zoccali, F.M. Cambareri, G. Parlongo (Reggio Calabria); A. Balducci, M. Gamerini, G. Sorbo (Rome); E. Fanciulli, P. Freddi, E. Balestra (Torrette di Ancona); F. Quarello, R. Boero, S. Borsa, C. Mossara (Turin); A. Fabbri, E. degli Esposti, C. Baraccani, A. Sturani, M. Gentile (Ravenna); A. Baraldi, M.R. Federico (Carpi); the Netherlands — A. van den Meiracker, J. Rutten, J. Wijberga (Rotterdam); H.A.H. Kaasjager, L.J. Reichert (Arnhem); J. Breed (Weert); A. Hollander, P. van Meurs, F. Ciggaar, P. van Hoek ('s-Hertogenbosch); P.J. Smak Gregoor (Dordrecht); S. Landewé-Cleuren (Maastricht); P. Viergever, R. Timmerman (Den Helder); R.P. Verhoeven, J. Barendregt, R. Lieverse, J. Smit, S. Radema, M.A. van Dijk, T. van Bemmel (Apeldoorn); A.J. Woittiez, F. Visser (Almelo); Spain — J. Alegre Martin, C. Aleman Llanso, M. Duran Tabena, J. Recio Iglesias, T. Soriano Sanchez, L. Comas, X. Farres, A. Ledesma Casteltort, M. Terns, P. Fernandez, F. Gonzales-N, F. Ortiz-Herbener, A. Oliveras, S. Vazquez, A. Martinez Castelao, F. Moreso Mateos, M.T. Gonzalez Alvarez (Barcelona); J. Redon, A. Casanova, J. Gorriz, P. Molina Vila, A. Priego (Valencia); L. Ruilope, C. Roldan, J. Segura, C. Campo, A. Calle Pascual, J. Garcia Honduvilla, F. de Alvaro, O. Costero Fernandez, S. Garcia de Vinvera, M. Goicoechea, J. Luño (Madrid); J. Olivan, J. Pizarro Nunez, E. Gonzales-Serna, A. Rodriguez Botaro (Seville); P. Gomez, M. Eady Alonso (Cadiz); L. De Teresa Parreno, P. Garcia Hermosa, J. Gomez Gomez, S. Fuentes Luri, J. Blazquez (Alicante); P. Aranda (Málaga); C. Calvo, M. Rodriguez Fernandez, J. Lopez Paz (Coruña); United Kingdom — G. Viberti, J. Karalliedde, V. Mirenda, L. Gnudi (London); A. Rees, A. Roberts (Cardiff); J. Reckless, A. Robinson, R.Y. Mukhtar, J. Vora, A. Joshi, H. White, J. Franklin (Bath); J. Walker, T. Sandeep, A. Mukhtar, R. Gray (Livingston); S. Heller, A. Mackie, S.H. Song (Sheffield); J. O'Hare, M.V. Chittari, K. Kos, M. Pierides (Rugby); Romania — M. Voiculescu, N. Caceaune, L. Iliescu, R. Bobeica, C. Ionescu, G. Ismail, L. Luca, G. Tatu-Chitoiu, S. Cronaciu, R. Jumatate, D. Zamfir (Bucharest); M. Stefanescu, D. Muntoi, D. Dobreanu, D. Cromos, G. Dogaru, C. Caldararu (Tg. Mures); D. Zdrenghea, C. Roman, A. Malai, M. Cebanu, M. Ostace, D. Pop, R. Rosu (Cluj-Napoca); R. Mihaila, R. Mihaila, E. Rezi, M. Strugariu, M. Deac (Sibiu); Russia — V. Zadionchenko, T. Adasheva, O. Demicheva, M. Antsiferov, O. Koteshkova, I. Sretenskaya, K. Tsipuria, E. Vasilieva, I. Fomina, A. Tarzimanova, A. Vasileva, S. Martsevich, J. Semenova, A. Serazhim, V. Voronina, N. Dmitrieva (Moscow); O. Ershova, P. Kumzerov, N. Borisova, E. Ohapkina, E. Bolshakova (Yaroslavl); O. Lantsevsa, L. Strezhova, T. Terentieva, I. Karpova, E. Ostrovskaya, V. Panina (Saint Petersburg); Argentina — C. Majul, O. Paez, P. Puleio, M. Visser, I. Sinay, M. Nepote, A. Elbert, H. Beresan (Buenos Aires); L. Juncos, N. Garcia, M. Orias, M. Belen Barron, P. Novoa (Cordoba); United States — A. Wynne, J. Conrow (Topeka, KS); M. Rendell, J. Lane (Omaha); D. Robertson (Atlanta); R. Solomon (Burlington, VT); E. Himot (Marietta, GA); S. Schmidt (Philadelphia); W. Spisak (Portland, OR); J. Mossberg (Eugene, OR); R. Graf (Tacoma, WA); R. Cooper (Tempe, AZ); R. Ouseph (Louisville, KY); J. Liljenquist (Idaho Falls, ID); M. Seidner (Lansdale, PA); R. Culpepper, F. Lester (Mobile, AL); B. Wood, R. Butin (Kansas City, MO); V. Ram, R. Sachson, R. Toto, B. Zamora (Dallas); R. Busch (Albany, NY); K. Cohen (Golden, CO); A. Barreto (Oklahoma City); K. Hillner (Bryan, TX); N.P. Kopyt (Allentown, PA); R. Lipetz (Spring Valley, CA); J. LaSalle (Excelsior Springs, MO); J. Robertson (Riverside, CA); J. Mageli (St. Paul, MN); R. Cherlin (Los Gatos, CA); P. Snell (Greer, SC); E. Dyess (Jackson, MS); N. Sapin (Glendale, AZ); M. Reeves (Chattanooga, TN); P. Suchinda (Sumter, SC); T. Fagan, M. Parker (Tucson, AZ); D. Martinez (Moreno Valley, CA); R. Arakaki (Honolulu); N. Bohannon (San Francisco); M. Moustafa (Orangeburg, SC); A. Chen (Pensacola, FL); E. Barranco (Ponce, PR).
- References
References
1
Luetscher JA ,Kraemer FB ,Wilson DM ,Schwartz HC ,Bryer-Ash M . Increased plasma inactive renin in diabetes mellitus: a marker of microvascular complications. N Engl J Med 1985;312:1412-1417
Full Text | Web of Science | Medline2
Parving H-H, Mauer M, Ritz E. Diabetic nephropathy. In: Brenner BM, ed. Brenner & Rector's the kidney. 8th ed. Vol. 2. Philadelphia: Elsevier, 2008:1265-98.
3
Brenner BM ,Cooper ME ,de Zeeuw D , et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
Full Text | Web of Science | Medline4
Lewis EJ ,Hunsicker LG ,Clarke WR , et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-860
Full Text | Web of Science | Medline5
Rossing P ,Hommel E ,Smidt UM ,Parving H-H . Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37:511-516
CrossRef | Web of Science | Medline6
de Zeeuw D ,Remuzzi G ,Parving H-H , et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-2320
CrossRef | Web of Science | Medline7
de Zeeuw D ,Remuzzi G ,Parving H-H , et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004;110:921-927
CrossRef | Web of Science | Medline8
Ibsen H ,Olsen MH ,Wachtell K , et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005;45:198-202
CrossRef | Web of Science | Medline9
Parving H-H ,Andersen AR ,Smidt UM ,Svendsen PA . Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1:1175-1179
CrossRef | Web of Science | Medline10
Lewis EJ ,Hunsicker LG ,Bain RP ,Rohde RD . The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462[Erratum, N Engl J Med 1993;330:152.]
Full Text | Web of Science | Medline11
Parving H-H ,Lehnert H ,Brochner-Mortensen J ,Gomis R ,Andersen S ,Arner P . The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-878
Full Text | Web of Science | Medline12
Gaede P ,Vedel P ,Larsen N ,Jensen GVH ,Parving H-H ,Pedersen O . Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393
Full Text | Web of Science | Medline13
Levey AS ,Bosch JP ,Lewis JB ,Greene T ,Rogers N ,Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-470
Web of Science | Medline14
Multizentrische Erprobung von Tina-quant-Albumin im Urin und β-N-Acetylglucosaminidase (β-NAG) im Urin. Wien Klin Wochenschr Suppl 1991;189:1-66
Medline15
Bartels H ,Bohmer M ,Heierli C . Serum kreatininbestimmung ohne enteiweissen. Clin Chim Acta 1972;37:193-197
CrossRef | Web of Science | Medline16
Rohlfing CL ,Little RR ,Wiedmeyer HM , et al. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care 2000;23:187-191[Erratum, Diabetes Care 2000;23:876.]
CrossRef | Web of Science | Medline17
Hollenberg NK . Is there a pharmacologic basis for combination renin axis blockade? Kidney Int 2005;68:2901-2903
CrossRef | Web of Science | Medline18
Rossing K ,Schjoedt KJ ,Jensen BR ,Boomsma F ,Parving H-H . Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005;68:1190-1198
CrossRef | Web of Science | Medline19
Hollenberg NK ,Parving H-H ,Viberti G , et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 2007;25:1921-1926
CrossRef | Web of Science | Medline20
Burgess E ,Muirhead N ,De Cotret P . A double-blind randomized controlled trial of high dose candesartan cilexetil in proteinuric renal disease -- results from SMART (Supra Maximal Atacand Renal Trial). J Am Soc Nephrol 2007;18:57A-57A21
Schjoedt KJ ,Rossing K ,Juhl TR , et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 2005;68:2829-2836
CrossRef | Web of Science | Medline22
Epstein M ,Williams GH ,Weinberger M , et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006;1:940-951
CrossRef | Web of Science | Medline23
Gradman AH ,Schmieder RE ,Lins RL ,Nussberger J ,Chiang Y ,Bedigian MP . Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-1018
CrossRef | Web of Science | Medline24
Staessen JA ,Li Y ,Richart T . Oral renin inhibitors. Lancet 2006;368:1449-1456[Erratum, Lancet 2006;368:2124.]
CrossRef | Web of Science | Medline25
Mogensen CE ,Neldam S ,Tikkanen I , et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) study. BMJ 2000;321:1440-1444
CrossRef | Web of Science | Medline26
Rossing K . Progression and remission of nephropathy in type 2 diabetes: new strategies of treatment and monitoring. Dan Med Bull 2007;54:79-98
Web of Science | Medline27
Bakris GL ,Ruilope L ,Locatelli F , et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007;72:879-885
CrossRef | Web of Science | Medline28
Hostetter TH ,Troy JL ,Brenner BM . Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 1981;19:410-415
CrossRef | Web of Science | Medline29
Trevisan R ,Tiengo A . Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. Am J Hypertens 1995;8:876-883
CrossRef | Web of Science | Medline30
Imanishi M ,Yoshioka K ,Konishi Y , et al. Glomerular hypertension as one cause of albuminuria in type II diabetic patients. Diabetologia 1999;42:999-1005
CrossRef | Web of Science | Medline31
Andersen S ,Blouch K ,Bialek J ,Deckert M ,Parving H-H ,Myers BD . Glomerular permselectivity in early stages of overt diabetic nephropathy. Kidney Int 2000;58:2129-2137
CrossRef | Web of Science | Medline32
Remuzzi A ,Ruggenenti P ,Mosconi L ,Pata V ,Viberti GC ,Remuzzi G . Effect of low-dose enalapril on glomerular size-selectivity in human diabetic nephropathy. J Nephrol 1993;6:36-4333
Langham RG ,Kelly DJ ,Cox AJ , et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002;45:1572-1576
CrossRef | Web of Science | Medline34
Palmer BF . Renal dysfunction complicating the treatment of hypertension. N Engl J Med 2002;347:1256-1261
Full Text | Web of Science | Medline35
Fisher ND ,Hollenberg NK . Unprecedented renal responses to direct blockade of the renin-angiotensin system with aliskiren, a novel renin inhibitor. Circulation 2007;116:Suppl II:II-556
CrossRef | Web of Science36
Hollenberg NK ,Price DA ,Fisher ND , et al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 2003;63:172-178
CrossRef | Web of Science | Medline37
Oparil S ,Yarows SA ,Patel S ,Fang H ,Zhang J ,Satlin A . Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221-229[Erratum, Lancet 2007;370:1542.]
CrossRef | Web of Science | Medline38
Uresin Y ,Taylor AA ,Kilo C , et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:190-198
CrossRef | Web of Science | Medline39
Nguyen G ,Delarue F ,Burckle C ,Bouzhir L ,Giller T ,Sraer JD . Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002;109:1417-1427
Web of Science | Medline40
Nguyen G ,Contrepas A ,Mueller DN , et al. Effect of the direct renin inhibitor aliskiren on (pro)renin receptor and profibrotic gene expression in kidneys of diabetic TG(mRen-2)27 rats. J Am Soc Nephrol 2007;18:60A-60A
CrossRef | Web of Science41
Feldman DL ,Jin L ,Xuan H ,Miserindino-Molteni R . Effect of the direct renin inhibitor (DRI) aliskiren on renal gene expression of pro-fibrotic molecules in experimental hypertensive diabetic nephropathy. J Am Soc Nephrol 2007;18:168A-168A
CrossRef | Web of Science42
Phillips L ,Dai T ,Feldman DL ,LaPage J ,Adler SG . Aliskiren attenuates high-glucose induced extracellular matrix and protects against cell death in cultured podocytes (Pods). J Am Soc Nephrol 2007;18:169A-169A43
Kelly DJ ,Zhang Y ,Moe G ,Naik G ,Gilbert RE . Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007;50:2398-2404
CrossRef | Web of Science | Medline
- Citing Articles (282)
Citing Articles
1
Ayako Sato, Hoglan Piao, Yukiko Nozawa, Tetsuo Morioka, Hiroshi Kawachi, Takashi Oite. (2012) Local delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis. Clinical and Experimental Nephrology
CrossRef2
Shinji Hagiwara, Phillip Kantharidis, Mark E. Cooper. (2012) What Are New Avenues for Renal Protection, in Addition to RAAS Inhibition?. Current Hypertension Reports
CrossRef3
Abdul Ali Abdellatif. (2012) The role of renin inhibition in treating the hypertensive patient with diabetes: a summary of preclinical and clinical evidence. Expert Review of Cardiovascular Therapy 10:2, 251-263
CrossRef4
John M. Flack, Anthony M. Yadao, Das Purkayastha, Rita Samuel, William B. White. (2012) Comparison of the effects of aliskiren/valsartan in combination versus valsartan alone in patients with Stage 2 hypertension. Journal of the American Society of Hypertension
CrossRef5
Sławomir Lizakowski, Leszek Tylicki, Marcin Renke, Przemysław Rutkowski, Zbigniew Heleniak, Maja Sławińska-Morawska, Ewa Aleksandrowicz, Wieslawa Łysiak-Szydłowska, Bolesław Rutkowski. (2012) Effect of aliskiren on proteinuria in non-diabetic chronic kidney disease: a double-blind, crossover, randomised, controlled trial. International Urology and Nephrology
CrossRef6
Yukinao Sakai, Tomoyuki Otsuka, Dai Ohno, Tsuneo Murasawa, Naoki Sato, Kyoichi Mizuno. (2012) Efficacy of Aliskiren in Japanese Chronic Kidney Disease Patients with Hypertension. Renal Failure1-6
CrossRef7
S. Kücükköylü, L.C. Rump. (2012) Arterielle Hypertonie als Progressionsfaktor der chronischen Niereninsuffizienz. Der Nephrologe
CrossRef8
Susan Kühnast, José W.A. van der Hoorn, Anita M. van den Hoek, Louis M. Havekes, Gene Liau, J. Wouter Jukema, Hans M.G. Princen. (2012) Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin. Journal of Hypertension 30:1, 107-116
CrossRef9
Yasutomi Higashikuni, Minoru Takaoka, Hiroshi Iwata, Kimie Tanaka, Yasunobu Hirata, Ryozo Nagai, Masataka Sata. (2012) Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice. Hypertension Research 35:1, 62-69
CrossRef10
Gil Chernin, Amir Gal-Oz, Eyal Ben-Assa, Idit F. Schwartz, Talia Weinstein, Doron Schwartz, Donald S. Silverberg. (2012) Secondary Prevention of Hyperkalemia With Sodium Polystyrene Sulfonate in Cardiac and Kidney Patients on Renin-Angiotensin-Aldosterone System Inhibition Therapy. Clinical Cardiology 35:1, 32-36
CrossRef11
Cesar Cerezo, Luis M. Ruilope, Julian Segura, Jose A. Garcia-Donaire, Juan J. de la Cruz, Jose R. Banegas, Bernard Waeber, Ton J. Rabelink, Franz H. Messerli. (2012) Microalbuminuria breakthrough under chronic renin–angiotensin–aldosterone system suppression. Journal of Hypertension 30:1, 204-209
CrossRef12
Jose Luis Gorriz, Alberto Martinez-Castelao. (2012) Proteinuria: detection and role in native renal disease progression. Transplantation Reviews 26:1, 3-13
CrossRef13
Patrick W.F. Hadoke. (2012) Does the combination of a renin inhibitor with a statin have potential for improved inhibition of atherosclerosis?. Journal of Hypertension 30:1, 40-41
CrossRef14
Azhar Rashikh, Shibli Jameel Ahmad, Krishna Kolappa Pillai, Abul Kalam Najmi. (2012) Aliskiren as a novel therapeutic agent for hypertension and cardio-renal diseases. Journal of Pharmacy and Pharmacologyno-no
CrossRef15
María José Soler, Marta Riera, Álex Gutierrez, Julio Pascual. (2012) New options and perspectives for proteinuria management after kidney transplantation. Transplantation Reviews 26:1, 44-52
CrossRef16
Xavier Belenfant, Wided Tabbi Anani, Mélanie Roland, Marie-Christine Mavel, Joelle Laederich. (2012) Traitement de l’insuffisance rénale chronique : stratégie thérapeutique. La Presse Médicale
CrossRef17
Andrew S Levey, Josef Coresh. (2012) Chronic kidney disease. The Lancet 379:9811, 165-180
CrossRef18
Mitchell H. Rosner, Joshua King, Peter Monteleone. 2011. Therapeutic Drug Development for Kidney Diseases. .
CrossRef19
Jeffrey M Turner, Carolyn Bauer, Matthew K Abramowitz, Michal L Melamed, Thomas H Hostetter. (2011) Treatment of chronic kidney disease. Kidney International
CrossRef20
James Matthew Luther, Nancy J. Brown. (2011) The renin–angiotensin–aldosterone system and glucose homeostasis. Trends in Pharmacological Sciences 32:12, 734-739
CrossRef21
Raymond R. Townsend, Alan D. Forker, Vaishali Bhosekar, Anthony Yadao, Deborah L. Keefe. (2011) Comparison of Aliskiren/Hydrochlorothiazide Combination Therapy and Amlodipine Monotherapy in Patients With Stage 2 Systolic Hypertension and Type 2 Diabetes Mellitus. The Journal of Clinical Hypertension 13:12, 889-897
CrossRef22
Norman K. Hollenberg, Naomi D.L. Fisher, Juerg Nussberger, George V. Moukarbel, Ebrahim Barkoudah, A.H. Jan Danser. (2011) Renal responses to three types of renin–angiotensin system blockers in patients with diabetes mellitus on a high-salt diet. Journal of Hypertension 29:12, 2454-2461
CrossRef23
Alejandro de la Sierra. (2011) Renin–angiotensin system blockade and reduction of cardiovascular risk: future perspectives. Expert Review of Cardiovascular Therapy 9:12, 1585-1591
CrossRef24
Tsukasa Nakamura, Eiichi Sato, Mayuko Amaha, Yasuhiro Kawagoe, Sayaka Maeda, Sho-ichi Yamagishi. (2011) Addition of aliskiren to angiotensin II receptor blockers ameliorates renal tubular injury and reduces intima media thickness of carotid artery in patients with diabetic nephropathy. International Journal of Cardiology
CrossRef25
Junji Yamauchi, Yugo Shibagaki, Keita Uehara, Takashi Yasuda, Kenjiro Kimura. (2011) Aliskiren-associated acute kidney injury in a patient with pre-existing chronic kidney disease and dilated cardiomyopathy. Clinical and Experimental Nephrology
CrossRef26
Jean-Jacques Boffa, Sophie Chauvet, Fabrice Mihout. (2011) Ralentir la progression de l’insuffisance rénale chronique : espoirs et déceptions. La réparation vasculaire du rein chronique. La Presse Médicale 40:11, 1065-1073
CrossRef27
A. Tomaschitz, S. Pilz, E. Ritz, A. Morganti, T. Grammer, K. Amrein, B. O. Boehm, W. Marz. (2011) Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. European Heart Journal 32:21, 2642-2649
CrossRef28
S. Belda-Rustarazo, I. Vallejo-Rodríguez, A. Molina-Carballo, J. Cabeza Barrera. (2011) Tratamiento de rescate con aliskiren en hipertensión maligna familiar en un lactante. Farmacia Hospitalaria 35:6, 343-344
CrossRef29
B. Chamontin, B. Bouhanick. (2011) HTA et diabète: nouveaux niveaux de preuves et prise en charge. Archives des Maladies du Coeur et des Vaisseaux - Pratique 2011:202, 24-30
CrossRef30
Fernando Elijovich, Cheryl L Laffer. (2011) Detrimental effects of dual ACEI–ARB therapy: is the (pro)renin receptor the culprit?. Kidney International 80:9, 911-914
CrossRef31
Anjay Rastogi, Mohamad Rashid, Richard F. Wright. (2011) Reducing Cardiorenal Risk Through Combination Therapy With a Direct Renin Inhibitor. The Journal of Clinical Hypertension 13:11, 848-855
CrossRef32
Niren K Shah, Rushab Choksi, Benjamin J Epstein. (2011) Less RAAS is more, or not. Expert Review of Cardiovascular Therapy 9:11, 1363-1365
CrossRef33
Emaad M. Abdel-Rahman, Lawand Saadulla, W. Brian Reeves, Alaa S. Awad. (2011) Therapeutic Modalities in Diabetic Nephropathy: Standard and Emerging Approaches. Journal of General Internal Medicine
CrossRef34
Haroon-Ur Rashid, Christian Mende. (2011) The Role of Direct Renin Inhibition in Clinical Practice. American Journal Cardiovascular Drugs 11:5, 303-315
CrossRef35
Ana Diez-Sampedro, Oliver Lenz, Alessia Fornoni. (2011) Podocytopathy in Diabetes: A Metabolic and Endocrine Disorder. American Journal of Kidney Diseases 58:4, 637-646
CrossRef36
J. L. Wilkinson-Berka, G. Tan, K. J. Binger, L. Sutton, K. McMaster, D. Deliyanti, G. Perera, D. J. Campbell, A. G. Miller. (2011) Aliskiren reduces vascular pathology in diabetic retinopathy and oxygen-induced retinopathy in the transgenic (mRen-2)27 rat. Diabetologia 54:10, 2724-2735
CrossRef37
Samir Parikh, Lee Hebert, Brad Rovin. (2011) Protecting the kidneys in lupus nephritis. International Journal of Clinical Rheumatology 6:5, 529-546
CrossRef38
W. Drummond, Y.M. Sirenko, E. Ramos, I. Baek, D.L. Keefe. (2011) Aliskiren as Add-On Therapy in the Treatment of Hypertensive Diabetic Patients Inadequately Controlled with Valsartan/HCT Combination. American Journal Cardiovascular Drugs 11:5, 327-333
CrossRef39
Zemin Cao, Mark E. Cooper. (2011) Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes. Acta Diabetologica
CrossRef40
S. Verma, M. Gupta, D. T. Holmes, L. Xu, H. Teoh, S. Gupta, S. Yusuf, E. M. Lonn. (2011) Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. European Heart Journal 32:17, 2135-2142
CrossRef41
Duska Dragun, Björn Hegner. (2011) Limitations of Targeting Rate-Limiting Step of Renin-Angiotensin-Aldosterone System in Experimental Chronic Allograft Nephropathy. Transplantation1
CrossRef42
Massimo Volpe, Roberto Pontremoli, Claudio Borghi. (2011) Direct Renin Inhibition. High Blood Pressure & Cardiovascular Prevention 18:3, 93-105
CrossRef43
Naomi DL. Fisher, Emma A. Meagher. (2011) Renin Inhibitors. The Journal of Clinical Hypertension 13:9, 662-666
CrossRef44
Alejandro Sierra, Jorge Salazar. (2011) What is the role of direct renin inhibitors in the treatment of the hypertensive diabetic patient?. Advances in Therapy 28:9, 716-727
CrossRef45
Francesco Paneni, Francesco Cosentino, Jasmine Passerini, Massimo Volpe. (2011) Is there any memory effect of blood pressure lowering in diabetes?. International Journal of Cardiology 151:3, 384-385
CrossRef46
Devasmita Choudhury, Moshe Levi. (2011) Kidney aging—inevitable or preventable?. Nature Reviews Nephrology 7:12, 706-717
CrossRef47
Henry A. Tran, Arthur Schwartzbard, Howard S. Weintraub. (2011) Role of RAAS Inhibition in the Prevention of Cardiovascular Disease. Current Treatment Options in Cardiovascular Medicine 13:4, 279-288
CrossRef48
Dae Eun Choi, Jin Young Jeong, Beom Jin Lim, Yoon-Kyung Chang, Ki-Ryang Na, Young-Tai Shin, Kang Wook Lee. (2011) Aliskiren Ameliorates Renal Inflammation and Fibrosis Induced by Unilateral Ureteral Obstruction in Mice. The Journal of Urology 186:2, 694-701
CrossRef49
Massimo Volpe, Francesco Cosentino, Giuliano Tocci, Francesca Palano, Francesco Paneni. (2011) Antihypertensive Therapy in Diabetes: The Legacy Effect and RAAS Blockade. Current Hypertension Reports 13:4, 318-324
CrossRef50
Daisuke Koya, Shin-ichi Araki, Masakazu Haneda. (2011) Therapeutic management of diabetic kidney disease. Journal of Diabetes Investigation 2:4, 248-254
CrossRef51
Ehud Grossman, Franz H. Messerli. (2011) Management of Blood Pressure in Patients With Diabetes. American Journal of Hypertension 24:8, 863-875
CrossRef52
Michelle W Krause, Vivian A Fonseca, Sudhir V Shah. (2011) Combination inhibition of the renin–angiotensin system: is more better?. Kidney International 80:3, 245-255
CrossRef53
Ikechi G Okpechi, Brian L Rayner. (2011) Impact of recent landmark clinical trials on hypertension treatment. Clinical Investigation 1:8, 1141-1154
CrossRef54
S. Methven, J. P. Traynor, M. D. Hair, D. S. J. O'Reilly, C. J. Deighan, M. S. MacGregor. (2011) Stratifying risk in chronic kidney disease: an observational study of UK guidelines for measuring total proteinuria and albuminuria. QJM 104:8, 663-670
CrossRef55
Merlin C Thomas, Per-Henrik Groop. (2011) New approaches to the treatment of nephropathy in diabetes. Expert Opinion on Investigational Drugs 20:8, 1057-1071
CrossRef56
Xi Shi, Chen Yan, Sergiy M. Nadtochiy, Jun-Ichi Abe, Paul S. Brookes, Bradford C. Berk. (2011) p90 ribosomal S6 kinase regulates activity of the renin–angiotensin system: A pathogenic mechanism for ischemia–reperfusion injury. Journal of Molecular and Cellular Cardiology 51:2, 272-275
CrossRef57
William B. White, Robert Bresalier, Allen P. Kaplan, Biff F. Palmer, Robert H. Riddell, Anastasia Lesogor, William Chang, Deborah L. Keefe. (2011) Safety and Tolerability of the Direct Renin Inhibitor Aliskiren in Combination With Angiotensin Receptor Blockers and Thiazide Diuretics: A Pooled Analysis of Clinical Experience of 12,942 Patients. The Journal of Clinical Hypertension 13:7, 506-516
CrossRef58
C. E. Jackson, M. R. MacDonald, M. C. Petrie, S. D. Solomon, B. Pitt, R. Latini, A. P. Maggioni, B. A. Smith, M. F. Prescott, J. Lewsey, J. J. V. McMurray, . (2011) Associations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study. European Journal of Heart Failure 13:7, 746-754
CrossRef59
Hiddo J. Lambers Heerspink. (2011) Therapeutic Approaches in Lowering Albuminuria: Travels Along the Renin-Angiotensin-Aldosterone-System Pathway. Advances in Chronic Kidney Disease 18:4, 290-299
CrossRef60
K.A. Connelly, A. Advani, S. Advani, Y. Zhang, K. Thai, S. Thomas, H. Krum, D.J. Kelly, R.E. Gilbert. (2011) Combination Angiotensin Converting Enzyme and Direct Renin Inhibition in Heart Failure following Experimental Myocardial Infarction. Cardiovascular Therapeuticsno-no
CrossRef61
Elke Wühl, Franz Schaefer. (2011) Managing kidney disease with blood-pressure control. Nature Reviews Nephrology 7:8, 434-444
CrossRef62
S. C. W. Tang, M. Lin, S. Tam, W. S. Au, M. K. M. Ma, D. Y. H. Yap, Y. W. Ho, K. N. Lai. (2011) Aliskiren combined with losartan in immunoglobulin A nephropathy: an open-labeled pilot study. Nephrology Dialysis Transplantation
CrossRef63
Pascal Meier, Marc P Maillard, Jacqueline R Meier, Sylvie Tremblay, Thierry Gauthier, Michel Burnier. (2011) Combining blockers of the renin-angiotensin system or increasing the dose of an angiotensin II receptor antagonist in proteinuric patients: a randomized triple-crossover study. Journal of Hypertension 29:6, 1228-1235
CrossRef64
Dagmara Hering, Murray D Esler, Henry Krum, Felix Mahfoud, Michael Böhm, Paul A Sobotka, Markus P Schlaich. (2011) Recent advances in the treatment of hypertension. Expert Review of Cardiovascular Therapy 9:6, 729-744
CrossRef65
Louis Kuritzky, Robert Toto, Peter Van Buren. (2011) Identification and Management of Albuminuria in the Primary Care Setting. The Journal of Clinical Hypertension 13:6, 438-449
CrossRef66
Niloofar Nobakht, Mohammad Kamgar, Anjay Rastogi, Robert W. Schrier. (2011) Limitations of angiotensin inhibition. Nature Reviews Nephrology 7:6, 356-359
CrossRef67
Luca De Nicola, Pasquale Zamboli, Vincenzo Bellizzi, Giovanna Stanzione, Domenico Russo, Felice Nappi, Maristella Minco, Paolo Chiodini, Giuseppe Conte, Roberto Minutolo. (2011) Antiproteinuric Response to Add-on Aliskiren in Proteinuric Patients Treated With Dual Blockade of the Renin-Angiotensin System: A 12-Month Prospective Uncontrolled Study. American Journal of Kidney Diseases 57:6, 961-963
CrossRef68
Takahito Moriyama, Yuki Tsuruta, Chiari Kojima, Mitsuyo Itabashi, Hidekazu Sugiura, Takashi Takei, Tetsuya Ogawa, Keiko Uchida, Ken Tsuchiya, Kosaku Nitta. (2011) Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. International Urology and Nephrology
CrossRef69
S. D. Solomon, S. Hee Shin, A. Shah, H. Skali, A. Desai, L. Kober, A. P. Maggioni, J. L. Rouleau, R. Y. Kelly, A. Hester, J. J. V. McMurray, M. A. Pfeffer, . (2011) Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. European Heart Journal 32:10, 1227-1234
CrossRef70
Margaret A. Fitzgerald. (2011) Hypertension treatment update: Focus on direct renin inhibition. Journal of the American Academy of Nurse Practitioners 23:5, 239-248
CrossRef71
Michel Burnier, Grégoire Wuerzner. (2011) Pharmacokinetic evaluation of losartan. Expert Opinion on Drug Metabolism & Toxicology 7:5, 643-649
CrossRef72
Fadi G Hage, Sulaf J Mansur, Suzanne Oparil. (2011) Rationale for the use of multiple blockers of the renin–angiotensin–aldosterone system in specific patient populations. Therapy 8:3, 227-236
CrossRef73
M. Azizi, M. Frank, O. Steichen, A. Blanchard. (2011) Intérêts et limites de l’inhibition de la rénine par l’aliskiren. Annales Pharmaceutiques Françaises 69:3, 142-150
CrossRef74
Qianni Cheng, Po Sing Leung. (2011) An update on the islet renin–angiotensin system. Peptides 32:5, 1087-1095
CrossRef75
Mark D. Huffman, Deepak Bhatnagar. (2011) Novel Treatments for Cardiovascular Disease Prevention. Cardiovascular Therapeuticsno-no
CrossRef76
Dengfeng Gao, Ning Ning, Xiaolin Niu, Jin Wei, Ping Sun, Guanghua Hao. (2011) Aliskiren vs. Angiotensin Receptor Blockers in Hypertension: Meta-Analysis of Randomized Controlled Trials. American Journal of Hypertension 24:5, 613-621
CrossRef77
Yoshiko Mizuno, Robert F Jacob, R Preston Mason. (2011) Combined use of calcium channel blockers and inhibitors of the renin–angiotensin system for treating hypertension. Therapy 8:3, 247-260
CrossRef78
Jeanette M. Wood, Jürgen Maibaum. 2011. Discovery and Development of Aliskiren, the First-in-Class Direct Renin Inhibitor for the Treatment of Hypertension. , 263-296.
CrossRef79
Eberhard Ritz. (2011) Drug of Choice in the Management of Hypertension in Diabetes and Diabetic Nephropathy: Angiotensin-Converting Enzyme Inhibitors. The Journal of Clinical Hypertension 13:4, 285-289
CrossRef80
Y. S. Kang, M. H. Lee, H. K. Song, Y. Y. Hyun, J. J. Cha, G. J. Ko, S. H. Kim, J. E. Lee, J. Y. Han, D. R. Cha. (2011) Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Nephrology Dialysis Transplantation 26:4, 1194-1204
CrossRef81
Athanasios E. Raptis, Konstantinos P. Markakis, Maria C. Mazioti, Sotirios A. Raptis, George D. Dimitriadis. (2011) What the radiologist needs to know about the diabetic patient. Insights into Imaging 2:2, 193-203
CrossRef82
Amitabh Dash, Rituparna Maiti, Tejaswi Kumar Akantappa Bandakkanavar, Bajrang Lal Pandey. (2011) Novel Drug Treatment for Diabetic Nephropathy. Hong Kong Journal of Nephrology 13:1, 19-26
CrossRef83
E. Wühl, F. Schaefer. (2011) Kinder mit chronischer Niereninsuffizienz. Der Nephrologe 6:2, 169-176
CrossRef84
Hideyasu Kiyomoto, Kumiko Moriwaki. (2011) Chronic blockade of the (pro)renin receptor ameliorates the kidney damage in the non-clipped kidney of Goldblatt hypertension. Hypertension Research 34:3, 289-291
CrossRef85
Oliver Gross, Rainer Girgert, Diana Rubel, Johanna Temme, Stephanie Theissen, Gerhard-Anton Müller. (2011) Renal Protective Effects of Aliskiren Beyond Its Antihypertensive Property in a Mouse Model of Progressive Fibrosis. American Journal of Hypertension 24:3, 355-361
CrossRef86
J.-M. Halimi, Rédigé par D. Obreja. (2011) Protéger les reins des hypertendus. Archives des Maladies du Coeur et des Vaisseaux - Pratique 2011, S7-S9
CrossRef87
A. de la Sierra. (2011) Prevención de la progresión y regresión de la lesión orgánica. Estrategias de futuro. Revista Clínica Española 211, 8-14
CrossRef88
Howard S. Weintraub, Henry Tran, Arthur Schwartzbard. (2011) Potential Benefits of Aliskiren Beyond Blood Pressure Reduction. Cardiology in Review 19:2, 90-94
CrossRef89
Susumu Ogawa, Kazuhiro Nako, Masashi Okamura, Miho Senda, Takefumi Mori, Sadayoshi Ito. (2011) Aliskiren reduces albuminuria and oxidative stress, and elevates glomerular filtration rates in Japanese patients with advanced diabetic nephropathy. Hypertension Research 34:3, 400-401
CrossRef90
2011. Diabetic Renal Disease. , 156-182.
CrossRef91
Joanne Chang, Weiyi Yang, Kristijan H. Kahler, Thomas Fellers, John Orloff, Arielle G. Bensimon, Andrew P. Yu, Chun-Po Steve Fan, Eric Q. Wu. (2011) Compliance, Persistence, Healthcare Resource Use, and Treatment Costs Associated with Aliskiren plus ARB versus ACE Inhibitor plus ARB Combination Therapy. American Journal Cardiovascular Drugs 11:1, 21-32
CrossRef92
Graziano Riccioni. (2011) Aliskiren in the Treatment of Hypertension and Organ Damage. Cardiovascular Therapeutics 29:1, 77-87
CrossRef93
Helmy M. Siragy. (2011) Rationale for Combining a Direct Renin Inhibitor with other Renin- Angiotensin System Blockers. Focus on Aliskiren and Combinations. Cardiovascular Drugs and Therapy 25:1, 87-97
CrossRef94
Anookh Mohanan, Ram Gupta, Amita Dubey, Vikrant Jagtap, Appaji Mandhare, Ramesh C. Gupta, Vijay Chauthaiwale, Chaitanya Dutt. (2011) TRC120038, a Novel Dual AT1/ETA Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats. International Journal of Hypertension 2011, 1-12
CrossRef95
M. Gheorghiade, M. Albaghdadi, F. Zannad, G. C. Fonarow, M. Bohm, C. Gimpelewicz, J. Botha, S. Moores, E. F. Lewis, H. Rattunde, A. Maggioni, , M. Gheorghiade, A. Maggioni, G. C. Fonarow, M. Bohm, F. Zannad, S. Solomon, E. Lewis, P. Finn, H. Hartley, L. Weinrach, E. Barkoudah, C. Duong, A. Rogers, K. Swedberg, S. Pocock, B. Pitt, J. S. Borer, J. Rouleau, M. Wibberg. (2011) Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). European Journal of Heart Failure 13:1, 100-106
CrossRef96
Susan J. Allison. (2011) Diabetic nephropathy: Aliskiren as an add-on treatment reduces albuminuria in patients with diabetes. Nature Reviews Nephrology 7:1, 1-1
CrossRef97
F. M. Tedla, A. Brar, R. Browne, C. Brown. (2011) Hypertension in Chronic Kidney Disease: Navigating the Evidence. International Journal of Hypertension 2011, 1-9
CrossRef98
Yoshitaka Maeda, Yuya Araki, Tomomi Uno, Keisuke Nishigaki, Naoto Inaba. (2011) Successful Treatment of Hypertension in Anuric Hemodialysis Patients with a Direct Renin Inhibitor, Aliskiren. Journal of Rural Medicine 6:1, 26-31
CrossRef99
Ikko Ohara, Mitsuo Tanimoto, Tomohito Gohda, Takahiko Yamazaki, Shinji Hagiwara, Maki Murakoshi, Tatsuya Aoki, Hitoe Toyoda, Yuji Ishikawa, Kazuhiko Funabiki, Satoshi Horikoshi, Yasuhiko Tomino. (2011) Effect of Combination Therapy with Angiotensin Receptor Blocker and 1,25-Dihydroxyvitamin D3 in Type 2 Diabetic Nephropathy in KK-Ay/Ta Mice. Nephron Experimental Nephrology 117:4, 124-132
CrossRef100
Anastasios Makris, Maria Seferou, Dimitris P. Papadopoulos. (2011) Resistant Hypertension Workup and Approach to Treatment. International Journal of Hypertension 2011, 1-10
CrossRef101
Peter N. Van Buren, Robert Toto. (2011) Hypertension in Diabetic Nephropathy: Epidemiology, Mechanisms, and Management. Advances in Chronic Kidney Disease 18:1, 28-41
CrossRef102
Domenic A. Sica. (2011) Pharmacologic Issues in Treating Hypertension in CKD. Advances in Chronic Kidney Disease 18:1, 42-47
CrossRef103
Yan Chun Li. 2011. Vitamin D and the Renin-Angiotensin System. , 707-723.
CrossRef104
Pierre Nantel, Paul René de Cotret. (2010) The evolution of angiotensin blockade in the management of cardiovascular disease. Canadian Journal of Cardiology 26, 7E-13E
CrossRef105
Rajesh Krishna, John A Wagner. (2010) Applications of ‘decisionable’ biomarkers in cardiovascular drug development. Biomarkers in Medicine 4:6, 815-827
CrossRef106
Vivencio Barrios, Carlos Escobar. (2010) Aliskiren in the Management of Hypertension. American Journal Cardiovascular Drugs 10:6, 349-358
CrossRef107
Sulaf J. Mansur, Fadi G. Hage, Suzanne Oparil. (2010) Have the Renin-Angiotensin-Aldosterone System Perturbations in Cardiovascular Disease Been Exhausted?. Current Cardiology Reports 12:6, 450-463
CrossRef108
Pitchai Balakumar, Gowraganahalli Jagadeesh. (2010) Cardiovascular and Renal Pathologic Implications of Prorenin, Renin, and the (Pro)renin Receptor: Promising Young Players From the Old Renin-Angiotensin-Aldosterone System. Journal of Cardiovascular Pharmacology 56:5, 570-579
CrossRef109
Dick de Zeeuw, Rajiv Agarwal, Michael Amdahl, Paul Audhya, Daniel Coyne, Tushar Garimella, Hans-Henrik Parving, Yili Pritchett, Giuseppe Remuzzi, Eberhard Ritz, Dennis Andress. (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. The Lancet 376:9752, 1543-1551
CrossRef110
Giovanna Leoncini, Francesca Viazzi, Roberto Pontremoli. (2010) Chronic Kidney Disease and Albuminuria in Arterial Hypertension. Current Hypertension Reports 12:5, 335-341
CrossRef111
Michael R. Lattanzio, Matthew R. Weir. (2010) Does Blockade of the Renin-Angiotensin-Aldosterone System Slow Progression of All Forms of Kidney Disease?. Current Hypertension Reports 12:5, 369-377
CrossRef112
William B. White, Robert Bresalier, Allen P. Kaplan, Biff F. Palmer, Robert H. Riddell, Anastasia Lesogor, William Chang, Deborah L. Keefe. (2010) Safety and Tolerability of the Direct Renin Inhibitor Aliskiren: A Pooled Analysis of Clinical Experience in More Than 12,000 Patients With Hypertension. The Journal of Clinical Hypertension 12:10, 765-775
CrossRef113
M. Cozzolino, M. Ketteler, D. Zehnder. (2010) The vitamin D system: a crosstalk between the heart and kidney. European Journal of Heart Failure 12:10, 1031-1041
CrossRef114
Kevin V. Lemley. (2010) When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes. Pediatric Nephrology 25:10, 2021-2034
CrossRef115
L. Tomasoni, S. Sitia, C. Borghi, A.F.G. Cicero, C. Ceconi, F. Cecaro, A. Morganti, V. De Gennaro Colonna, M. Guazzi, L. Morricone, A.E. Malavazos, P. Marino, C. Cavallino, Y. Shoenfeld, M. Turiel. (2010) Effects of treatment strategy on endothelial function. Autoimmunity Reviews 9:12, 840-844
CrossRef116
Sean T. Duggan, Claudine M. Chwieduk, Monique P. Curran. (2010) Aliskiren. Drugs 70:15, 2011-2049
CrossRef117
George Bakris, Joseph Vassalotti, Eberhard Ritz, Christoph Wanner, George Stergiou, Mark Molitch, Richard Nesto, George A Kaysen, James R Sowers. (2010) National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney International 78:8, 726-736
CrossRef118
Colin M. Tice, Gerard M. McGeehan, David A. Claremon. 2010. Antihypertensives: Renin Inhibitors. .
CrossRef119
F. H. Messerli, J. A. Staessen, F. Zannad. (2010) Of fads, fashion, surrogate endpoints and dual RAS blockade. European Heart Journal 31:18, 2205-2208
CrossRef120
Michael R Lattanzio, Matthew R Weir. (2010) Have we fallen off target with concerns surrounding dual RAAS blockade?. Kidney International 78:6, 539-545
CrossRef121
T. Feldkamp. (2010) Vitamin D zur Behandlung der diabetischen Nephropathie. Der Nephrologe 5:5, 417-418
CrossRef122
George L Bakris. (2010) Dual RAAS blockade is desirable in kidney disease: Con. Kidney International 78:6, 546-549
CrossRef123
Lalitha De Silva, Matthew R Weir. (2010) Renin inhibition and microalbuminuria development: meaningful predictor of kidney disease progression. Current Opinion in Nephrology and Hypertension 19:5, 437-443
CrossRef124
J. Díez. (2010) ¿Qué ha cambiado en el manejo actual de la hipertensión arterial desde el punto de vista renal?. Revista Clínica Española 210, 12-17
CrossRef125
P. Aguiar-Souto, S. Raposeiras-Roubín, J.R. González-Juanatey. (2010) Novedades en el último año en el planteamiento terapéutico de la cardiopatía hipertensiva, de la cardiopatía isquémica y de la fibrilación auricular. Revista Clínica Española 210, 2-11
CrossRef126
S. Hirsch. (2010) Dual renin-angiotensin-aldosterone system inhibition: boon or bust?. International Journal of Clinical Practice 64:10, 1337-1340
CrossRef127
Sudhir V. Shah. (2010) Progress Toward Novel Treatments for Chronic Kidney Disease. Journal of Renal Nutrition 20:5, S122-S126
CrossRef128
W David Strain, Salim Elyas, Phillip E Gates, Angela C Shore. (2010) Age-related change in endothelial and microvessel function and therapeutic consequences. Reviews in Clinical Gerontology 20:03, 161-170
CrossRef129
F. Persson, P. Rossing, H. Reinhard, T. Juhl, C. D. A. Stehouwer, C. Schalkwijk, A. H. J. Danser, F. Boomsma, E. Frandsen, H.-H. Parving. (2010) Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia 53:8, 1576-1580
CrossRef130
Robert C. Stanton. (2010) Use of Medications to Lower Urine Protein Level in Patients With Diabetic Kidney Disease. Current Diabetes Reports 10:4, 257-260
CrossRef131
Gabin Sihn, Anthony Rousselle, Larissa Vilianovitch, Celine Burckle, Michael Bader. (2010) Physiology of the (pro)renin receptor: Wnt of change?. Kidney International 78:3, 246-256
CrossRef132
Markus P. Schlaich, Henry Krum, Murray D. Esler. (2010) New Therapeutic Approaches to Resistant Hypertension. Current Hypertension Reports 12:4, 296-302
CrossRef133
Seung-Hyun Ko, Wenhong Cao, Zhenqi Liu. (2010) Hypertension Management and Microvascular Insulin Resistance in Diabetes. Current Hypertension Reports 12:4, 243-251
CrossRef134
Victor J. Cee. 2010. Aliskiren (Tekturna), The First-in-Class Renin Inhibitor for Hypertension. , 141-158.
CrossRef135
Sally M. Marshall, Allan Flyvbjerg. 2010. Diabetic Nephropathy. , 599-614.
CrossRef136
Masaru Iwai, Harumi Kanno, Yumiko Tomono, Shinji Inaba, Izumi Senba, Megumi Furuno, Masaki Mogi, Masatsugu Horiuchi. (2010) Direct renin inhibition improved insulin resistance and adipose tissue dysfunction in type 2 diabetic KK-Ay mice. Journal of Hypertension 28:7, 1471-1481
CrossRef137
Barry M. Wall. (2010) Cardiorenal Risk Factors. The American Journal of the Medical Sciences 340:1, 25-29
CrossRef138
George L Bakris, Anil Bidani. (2010) More complete renin–angiotensin system blockade: better outcomes or smoke and mirrors. Journal of Hypertension 28:7, 1382-1383
CrossRef139
Alejandro de la Sierra, Luis Miguel Ruilope. (2010) ¿Es posible conseguir una mayor reducción de la morbimortalidad cardiovascular en los pacientes ya tratados con bloqueadores del sistema renina-angiotensina?. Medicina Clínica 135:5, 212-214
CrossRef140
Yan Chun Li. (2010) Renoprotective effects of vitamin D analogs. Kidney International 78:2, 134-139
CrossRef141
Christian Werner, Janine Pöss, Michael Böhm. (2010) Optimal Antagonism of the Renin-Angiotensin-Aldosterone System. Drugs 70:10, 1215-1230
CrossRef142
Eduardo Pimenta. (2010) Is There a Place on the Shelf for Aliskiren?. Current Cardiovascular Risk Reports 4:4, 264-270
CrossRef143
Yi-Fei Dong, Lei Liu, Zhong-Fang Lai, Eiichiro Yamamoto, Keiichiro Kataoka, Taishi Nakamura, Masaya Fukuda, Yoshiko Tokutomi, Hisato Nako, Hisao Ogawa, Shokei Kim-Mitsuyama. (2010) Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice. Journal of Hypertension 28:7, 1554-1565
CrossRef144
Dilip K Deb, Tao Sun, Kari E Wong, Zhongyi Zhang, Gang Ning, Yan Zhang, Juan Kong, Helen Shi, Anthony Chang, Yan Chun Li. (2010) Combined vitamin D analog and AT1 receptor antagonist synergistically block the development of kidney disease in a model of type 2 diabetes. Kidney International 77:11, 1000-1009
CrossRef145
Anne-Emilie Declèves, Kumar Sharma. (2010) New pharmacological treatments for improving renal outcomes in diabetes. Nature Reviews Nephrology 6:6, 371-380
CrossRef146
FAN FAN HOU, QIU GEN ZHOU. (2010) Optimal dose of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker for renoprotection. Nephrology 15, 57-60
CrossRef147
Piero Ruggenenti, Paolo Cravedi, Giuseppe Remuzzi. (2010) The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nature Reviews Nephrology 6:6, 319-330
CrossRef148
Mariyo Sakoda, Atsuhiro Ichihara, Asako Kurauchi-Mito, Tatsuya Narita, Kenichiro Kinouchi, Kanako Murohashi-Bokuda, Moin A. Saleem, Akira Nishiyama, Fumiaki Suzuki, Hiroshi Itoh. (2010) Aliskiren Inhibits Intracellular Angiotensin II Levels Without Affecting (Pro)renin Receptor Signals in Human Podocytes. American Journal of Hypertension 23:5, 575-580
CrossRef149
Zafar H Israili, Manuel Velasco, Valmore Bermúdez. (2010) Direct Renin Inhibitors as Antihypertensive Agents. American Journal of Therapeutics 17:3, 237-254
CrossRef150
David Benavente, Colin D. Chue, Charles J. Ferro. (2010) THE IMPORTANCE OF RENIN-ANGIOTENSIN BLOCKADE IN PATIENTS WITH CARDIO-RENAL DISEASE. Journal of Renal Care 36, 97-105
CrossRef151
Jula K. Inrig. (2010) Antihypertensive Agents in Hemodialysis Patients: A Current Perspective. Seminars in Dialysis 23:3, 290-297
CrossRef152
Chadban S, Howell M, Twigg S, Thomas M, Jerums G, Cass A, Campbell D, Nicholls K, Tong A, Mangos G, Stack A, MacIsaac RJ, Girgis S, Colagiuri R, Colagiuri S, Craig J. (2010) Prevention and management of chronic kidney disease in type 2 diabetes. Nephrology 15, S162-S194
CrossRef153
Matthew T James, Brenda R Hemmelgarn, Marcello Tonelli. (2010) Early recognition and prevention of chronic kidney disease. The Lancet 375:9722, 1296-1309
CrossRef154
David L Feldman. (2010) New insights into the renoprotective actions of the renin inhibitor aliskiren in experimental renal disease. Hypertension Research 33:4, 279-287
CrossRef155
Elke Wühl, Franz Schaefer. (2010) Can we slow the progression of chronic kidney disease?. Current Opinion in Pediatrics 22:2, 170-175
CrossRef156
Christian W. Mende. (2010) Application of Direct Renin Inhibition to Chronic Kidney Disease. Cardiovascular Drugs and Therapy 24:2, 139-149
CrossRef157
Jon Bergset, Eugene Storozynsky, John D Bisognano. (2010) Renin Inhibition for Hypertension: Selecting the Right Role for a New Class of Drug. American Journal of Therapeutics 17:2, 182-187
CrossRef158
Steven G. Chrysant. (2010) Current Status of Dual Renin Angiotensin Aldosterone System Blockade for the Treatment of Cardiovascular Diseases. The American Journal of Cardiology 105:6, 849-852
CrossRef159
Lionel Coltamai, Marc Maillard, Alexandra Simon, Bruno Vogt, Michel Burnier. (2010) Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans. Journal of Hypertension 28:3, 520-526
CrossRef160
Maartje CJ Slagman, Gerjan Navis, Gozewijn D Laverman. (2010) Dual blockade of the renin–angiotensin–aldosterone system in cardiac and renal disease. Current Opinion in Nephrology and Hypertension 19:2, 140-152
CrossRef161
Toshio Miyata, Charles van Ypersele de Strihou. (2010) Diabetic nephropathy: a disorder of oxygen metabolism?. Nature Reviews Nephrology 6:2, 83-95
CrossRef162
Michael Bader. (2010) Tissue Renin-Angiotensin-Aldosterone Systems: Targets for Pharmacological Therapy. Annual Review of Pharmacology and Toxicology 50:1, 439-465
CrossRef163
Carlos M. Ferrario. (2010) Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin–angiotensin–aldosterone system: Antihypertensive effects and benefits beyond BP control. Life Sciences 86:9-10, 289-299
CrossRef164
Tomoki Kosugi, Marcelo Heinig, Takahiro Nakayama, Seiichi Matsuo, Takahiko Nakagawa. (2010) eNOS Knockout Mice with Advanced Diabetic Nephropathy Have Less Benefit from Renin-Angiotensin Blockade than from Aldosterone Receptor Antagonists. The American Journal of Pathology 176:2, 619-629
CrossRef165
AH Jan Danser. (2010) The increase in renin during renin inhibition: does it result in harmful effects by the (pro)renin receptor?. Hypertension Research 33:1, 4-10
CrossRef166
Norman K. Hollenberg. (2010) Direct renin inhibition and the kidney. Nature Reviews Nephrology 6:1, 49-55
CrossRef167
Sadayoshi Ito, Noriko Nakura, Stephanie Le Breton, Deborah Keefe. (2010) Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertension Research 33:1, 62-66
CrossRef168
Steven A Yarows. (2010) Aliskiren/valsartan combination for the treatment of cardiovascular and renal diseases. Expert Review of Cardiovascular Therapy 8:1, 19-33
CrossRef169
Alberto Cordero, Lorenzo Fácila, Enrique Galve, Pilar Mazón. (2010) Novedades en hipertensión arterial y diabetes mellitus. Revista Española de Cardiología 63, 101-115
CrossRef170
Takafumi OKURA. (2010) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 41:2, 61S-62S
CrossRef171
Steen Neldam. (2010) Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?. Future Cardiology 6:1, 129-135
CrossRef172
Y. F. Dong, L. Liu, K. Kataoka, T. Nakamura, M. Fukuda, Y. Tokutomi, H. Nako, H. Ogawa, S. Kim-Mitsuyama. (2010) Aliskiren prevents cardiovascular complications and pancreatic injury in a mouse model of obesity and type 2 diabetes. Diabetologia 53:1, 180-191
CrossRef173
Chang Gyu Park. (2010) Update on Newer Antihypertensive Medicines. Journal of the Korean Medical Association 53:8, 717
CrossRef174
Atsuhiro Ichihara, Mariyo Sakoda, Asako Kurauchi-Mito, Tatsuya Narita, Kenichiro Kinouchi, Kanako Bokuda, Hiroshi Itoh. (2010) New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Characteristics and Usefulness of the Direct Renin Inhibitor Aliskiren. Journal of Pharmacological Sciences 113:4, 296-300
CrossRef175
Hiddo J Lambers Heerspink, Vlado Perkovic, Dick de Zeeuw. (2009) Renal and cardio-protective effects of direct renin inhibition: a systematic literature review. Journal of Hypertension 27:12, 2321-2331
CrossRef176
J.-M. Halimi, R. Asmar, J. Ribstein. (2009) Optimal nephroprotection: Use, misuse and misconceptions about blockade of the renin–angiotensin system. Lessons from the ONTARGET and other recent trials. Diabetes & Metabolism 35:6, 425-430
CrossRef177
Francesco Locatelli, Biff F. Palmer, Naoki Kashihara, Tevfik Ecder. (2009) Renal protective effect of RAAS blockade across the renal continuum, with a review of the efficacy and safety of valsartan. Current Medical Research and Opinion 25:12, 2933-2949
CrossRef178
Carolina R. C. Doorenbos, Jacob van den Born, Gerjan Navis, Martin H. de Borst. (2009) Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism. Nature Reviews Nephrology 5:12, 691-700
CrossRef179
Bryan Williams. (2009) The Year in Hypertension. Journal of the American College of Cardiology 55:1, 65-73
CrossRef180
Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J. Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Antony Heagerty, Sverre E. Kjeldsen, Wolfgang Kiowski, Jean Michel Mallion, Athanasios Manolis, Krzysztof Narkiewicz, Peter Nilsson, Michael H. Olsen, Karl Heinz Rahn, Josep Redon, José Rodicio, Luis Ruilope, Roland E. Schmieder, Harry A.J. Struijker-Boudier, Pieter A. Van Zwieten, Margus Viigimaa, Alberto Zanchetti. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Pressure 18:6, 308-347
CrossRef181
Michael W. Tempelhof. (2009) Comparative Role of Angiotensin Receptor Blockers Versus Other Agents in the Management of Hypertension, Cardiovascular Disease and Nephropathy. Southern Medical Journal 102:12, 1201-1202
CrossRef182
R. Haynes, P. Mason, K. Rahimi, M. J. Landray. (2009) Dual blockade of the renin-angiotensin system: are two better than one?. Nephrology Dialysis Transplantation 24:12, 3602-3607
CrossRef183
Rekha Pinto, Alan H. Gradman. (2009) Direct renin inhibition: An update. Current Hypertension Reports 11:6, 456-462
CrossRef184
Radko Komers. (2009) What is the role of renin inhibition in the treatment of diabetic kidney disease?. Current Diabetes Reports 9:6, 447-452
CrossRef185
Jan A Krikken, Gozewijn D Laverman, Gerjan Navis. (2009) Benefits of dietary sodium restriction in the management of chronic kidney disease. Current Opinion in Nephrology and Hypertension 18:6, 531-538
CrossRef186
Rigas G. Kalaitzidis, George L. Bakris. (2009) The current state of RAAS blockade in the treatment of hypertension and proteinuria. Current Cardiology Reports 11:6, 436-442
CrossRef187
Verena Freiberger, Kerstin Amann, Uwe Heemann, Helga Frank. (2009) Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation. Transplant International 22:11, 1110-1113
CrossRef188
Gianpaolo Reboldi, Giorgio Gentile, Fabio Angeli, Paolo Verdecchia. (2009) Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. Expert Review of Cardiovascular Therapy 7:11, 1349-1361
CrossRef189
Benjamin J Epstein, Steven M Smith, Rushab Choksi. (2009) Recent changes in the landscape of combination RAS blockade. Expert Review of Cardiovascular Therapy 7:11, 1373-1384
CrossRef190
Giuseppe Mancia, Stéphane Laurent, Enrico Agabiti-Rosei, Ettore Ambrosioni, Michel Burnier, Mark J Caulfield, Renata Cifkova, Denis Clément, Antonio Coca, Anna Dominiczak, Serap Erdine, Robert Fagard, Csaba Farsang, Guido Grassi, Hermann Haller, Anthony Heagerty, Sverre E Kjeldsen, Wolfgang Kiowski, Jean Michel Mallion, Athanasios Manolis, Krzysztof Narkiewicz, Peter Nilsson, Michael H Olsen, Karl Heinz Rahn, Josep Redon, José Rodicio, Luis Ruilope, Roland E Schmieder, Harry AJ Struijker-Boudier, Pieter A van Zwieten, Margus Viigimaa, Alberto Zanchetti. (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension 27:11, 2121-2158
CrossRef191
Ranjan Chanda, Andrew Z. Fenves. (2009) Hypertension in patients with chronic kidney disease. Current Hypertension Reports 11:5, 329-336
CrossRef192
Andrew S. Bomback, Robert Toto. (2009) Dual Blockade of the Renin–Angiotensin–Aldosterone System: Beyond the ACE Inhibitor and Angiotensin-II Receptor Blocker Combination. American Journal of Hypertension 22:10, 1032-1040
CrossRef193
Kunal Chaudhary, Ravi Nistala, Adam Whaley-Connell. (2009) Dual renin-angiotensin system blockade in the ONTARGET study: Clinically relevant risk for the kidney?. Current Hypertension Reports 11:5, 375-381
CrossRef194
, D. Koya, M. Haneda, S. Inomata, Y. Suzuki, D. Suzuki, H. Makino, K. Shikata, Y. Murakami, Y. Tomino, K. Yamada, S. I. Araki, A. Kashiwagi, R. Kikkawa. (2009) Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial. Diabetologia 52:10, 2037-2045
CrossRef195
Shailendra Kapoor. (2009) Aliskiren and Its Rapidly, Evolving Role in the Management of Cardio-Thoracic Diseases. Heart, Lung and Circulation 18:5, 372
CrossRef196
Bassam G. Abu Jawdeh, Mahboob Rahman. (2009) Blood pressure level and kidney disease progression: Do we really need to go to 130/80 mm Hg?. Current Hypertension Reports 11:5, 363-367
CrossRef197
Neeraj Dhaun, Iain M. MacIntyre, Christopher O.C. Bellamy, David C. Kluth. (2009) Endothelin Receptor Antagonism and Renin Inhibition as Treatment Options for Scleroderma Kidney. American Journal of Kidney Diseases 54:4, 726-731
CrossRef198
Sheldon W. Tobe, Monica O. Dai. (2009) Outcomes of antiproteinuric RAAS blockade: High-dose compared with dual therapy. Current Hypertension Reports 11:5, 345-353
CrossRef199
Jan Basile, Peter P. Toth. (2009) Angiotensin Receptor Blockers: Role in Hypertension Management, Cardiovascular Risk Reduction, and Nephropathy. Southern Medical Journal 102, S1-S12
CrossRef200
Rigas G Kalaitzidis, George L Bakris. (2009) Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease?. Current Opinion in Nephrology and Hypertension 18:5, 386-391
CrossRef201
C Venkata S Ram. (2009) Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease. Future Cardiology 5:5, 453-465
CrossRef202
György Jermendy. (2009) Hypertonia diabetes mellitusban. Orvosi Hetilap 150:39, 1813-1823
CrossRef203
Rainer Düsing, Felicity Sellers. (2009) ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Current Medical Research and Opinion 25:9, 2287-2301
CrossRef204
J. Díez. (2009) Enfoque nefrológico del bloqueo del sistema renina-angiotensina para el tratamiento de la hipertensión. Revista Clínica Española 209, 3-8
CrossRef205
Aldo J Peixoto, Marcelo Orias. (2009) Is there a role for direct renin inhibitors in chronic kidney disease?. Current Opinion in Nephrology and Hypertension 18:5, 397-403
CrossRef206
Kazuhiro Takahashi, Takuo Hirose, Nobuyoshi Mori, Ryo Morimoto, Masahiro Kohzuki, Yutaka Imai, Kazuhito Totsune. (2009) The renin–angiotensin system, adrenomedullins and urotensin II in the kidney: Possible renoprotection via the kidney peptide systems. Peptides 30:8, 1575-1585
CrossRef207
Rigas Kalaitzidis, George Bakris. (2009) Management of hypertension in patients with diabetes: the place of angiotensin-II receptor blockers. Diabetes, Obesity and Metabolism 11:8, 757-769
CrossRef208
Alan S. Maisel. (2009) Cardiovascular and Renal Surrogate Markers in the Clinical Management of Hypertension. Cardiovascular Drugs and Therapy 23:4, 317-326
CrossRef209
Ankur Gupta, Ambar Khaira, Bakshish Singh, Dipankar M. Bhowmik, Suresh C. Tiwari. (2009) Aliskiren as an antiproteinuric add-on therapy in primary membranous nephropathy. Clinical and Experimental Nephrology 13:4, 402-403
CrossRef210
Denis L. Clement. (2009) Treatment of hypertension in patients with peripheral arterial disease: An update. Current Hypertension Reports 11:4, 271-276
CrossRef211
Christos Chatzikyrkou, Jan Menne, Hermann Haller. (2009) Hypertonologie 2007–2008. Medizinische Klinik 104:8, 614-621
CrossRef212
Pitchai Balakumar, Mandeep Kumar Arora, Jayarami Reddy, Madhu B Anand-Srivastava. (2009) Pathophysiology of Diabetic Nephropathy: Involvement of Multifaceted Signalling Mechanism. Journal of Cardiovascular Pharmacology 54:2, 129-138
CrossRef213
Mauer, Michael, Zinman, Bernard, Gardiner, Robert, Suissa, Samy, Sinaiko, Alan, Strand, Trudy, Drummond, Keith, Donnelly, Sandra, Goodyer, Paul, Gubler, Marie Claire, Klein, Ronald, . (2009) Renal and Retinal Effects of Enalapril and Losartan in Type 1 Diabetes. New England Journal of Medicine 361:1, 40-51
Full Text214
Franz H. Messerli. (2009) Reply. Journal of the American College of Cardiology 54:3, 279-280
CrossRef215
J. Susie Woo, Jeffrey L. Probstfield. (2009) The role of ACE inhibitors and angiotensin receptor blockers in the treatment of hypertension and cardiovascular disease. Current Cardiovascular Risk Reports 3:4, 255-263
CrossRef216
Amgad N Makaryus, Samy I McFarlane. (2009) Treatment of hypertension in the diabetic patient. Therapy 6:4, 497-505
CrossRef217
Kathryn J Wiggins, Darren J Kelly. (2009) Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?. Kidney International 76:1, 23-31
CrossRef218
Graziano Riccioni, Nicola Vitulano, Nicolantonio D’Orazio, Fulvio Bellocci. (2009) Aliskiren, the first approved renin inhibitor: Clinical application and safety in the treatment of hypertension. Advances in Therapy 26:7, 700-710
CrossRef219
K.F. Hilgers. (2009) Das Renin-Angiotensin-System. Der Nephrologe 4:4, 351-361
CrossRef220
Helmut Geiger, Elizabeth Barranco, Manuel Gorostidi, Addison Taylor, Xiaoli Zhang, Zhihua Xiang, Jack Zhang. (2009) Combination Therapy With Various Combinations of Aliskiren, Valsartan, and Hydrochlorothiazide in Hypertensive Patients Not Adequately Responsive to Hydrochlorothiazide Alone. The Journal of Clinical Hypertension 11:6, 324-332
CrossRef221
Yasmin Pasha, Paul Gusbeth-Tatomir, Adrian Covic, David Goldsmith. (2009) Direct renin inhibitors: ONTARGET for success?. International Urology and Nephrology 41:2, 341-355
CrossRef222
Daniel A Duprez. (2009) Aliskiren: the next innovation in renin–angiotensin–aldosterone system blockade. Aging Health 5:3, 269-279
CrossRef223
Jan Basile. (2009) New Therapeutic Options in Patients Prone to Hypertension: A Focus on Direct Renin Inhibition and Aldosterone Blockade. The American Journal of the Medical Sciences 337:6, 438-444
CrossRef224
Amir Ravandi, Koon K Teo. (2009) Blocking the renin–angiotensin system: dual- versus mono-therapy. Expert Review of Cardiovascular Therapy 7:6, 667-674
CrossRef225
Nitin Khosla, Rigas Kalaitzidis, George L. Bakris. (2009) The Kidney, Hypertension, and Remaining Challenges. Medical Clinics of North America 93:3, 697-715
CrossRef226
Nigel A. Calcutt, Mark E. Cooper, Tim S. Kern, Ann Marie Schmidt. (2009) Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nature Reviews Drug Discovery 8:5, 417-430
CrossRef227
David S. H. Bell. (2009) Treatment of diabetic hypertension. Diabetes, Obesity and Metabolism 11:5, 433-444
CrossRef228
Olusegun L Amao. (2009) Angiotensin-converting enzyme 2 (ACE2) gene and protein expression in diabetic patients without nephropathy. Kidney International 75:10, 1118-1119
CrossRef229
R. Marín, M. Gorostidi, R. Álvarez-Navascués, S. García-Melendreras. (2009) Tratamiento de la hipertensión arterial en pacientes con enfermedad renal crónica. Evidencias e implicaciones. Medicina Clínica 132, 20-26
CrossRef230
H.-H. Parving, B. M. Brenner, John. J. V. McMurray, D. de Zeeuw, S. M. Haffner, S. D. Solomon, N. Chaturvedi, M. Ghadanfar, N. Weissbach, Z. Xiang, J. Armbrecht, M. A. Pfeffer. (2009) Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrology Dialysis Transplantation 24:5, 1663-1671
CrossRef231
G. Wolf. (2009) Diabetes und Niere – Update 2009. Der Diabetologe 5:3, 190-199
CrossRef232
Maha A. Mohamed, Matthew R. Weir. (2009) Renin Angiotensin System Inhibition in the Older Person: A Review. Clinics in Geriatric Medicine 25:2, 245-257
CrossRef233
Eugene A. Magee, James P. Lash. (2009) Aliskiren: An Overview of the First Direct Renin Inhibitor. Kidney 18:3, 117-120
CrossRef234
Mieke van den Heuvel, Wendy W. Batenburg, A.H. Jan Danser. (2009) Diabetic complications: A role for the prorenin–(pro)renin receptor–TGF-β1 axis?. Molecular and Cellular Endocrinology 302:2, 213-218
CrossRef235
Rajesh Kumar, Vivek P. Singh, Kenneth M. Baker. (2009) The intracellular renin-angiotensin system in the heart. Current Hypertension Reports 11:2, 104-110
CrossRef236
Varun Agrawal, Victor Marinescu, Mohit Agarwal, Peter A. McCullough. (2009) Cardiovascular implications of proteinuria: an indicator of chronic kidney disease. Nature Reviews Cardiology 6:4, 301-311
CrossRef237
I. Quack, L.C. Rump. (2009) Niere und Hypertonie. Der Internist 50:4, 410-422
CrossRef238
Apurv Khanna, William B. White. (2009) The Management of Hyperkalemia in Patients with Cardiovascular Disease. The American Journal of Medicine 122:3, 215-221
CrossRef239
Basil O Burney, Rigas G Kalaitzidis, George L Bakris. (2009) Novel therapies of diabetic nephropathy. Current Opinion in Nephrology and Hypertension 18:2, 107-111
CrossRef240
Ravi Nistala, Yongzhong Wei, James R. Sowers, Adam Whaley-Connell. (2009) Renin-angiotensin-aldosterone system-mediated redox effects in chronic kidney disease. Translational Research 153:3, 102-113
CrossRef241
M. Dalla Vestra, N. Simioni, A. Masiero. (2009) Renal effects of dual renin–angiotensin–aldosterone system blockade in patients with diabetic nephropathy. International Urology and Nephrology 41:1, 119-126
CrossRef242
Hae-Young Lee, Byung-Hee Oh. (2009) Cardio–renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program. Expert Review of Cardiovascular Therapy 7:3, 251-257
CrossRef243
Cynthia A Sanoski. (2009) Aliskiren: An Oral Direct Renin Inhibitor for the Treatment of Hypertension. Pharmacotherapy 29:2, 193-212
CrossRef244
Franz H. Messerli. (2009) The Sudden Demise of Dual Renin-Angiotensin System Blockade or the Soft Science of the Surrogate End Point. Journal of the American College of Cardiology 53:6, 468-470
CrossRef245
Juan Carlos Q Velez. (2009) The importance of the intrarenal renin–angiotensin system. Nature Clinical Practice Nephrology 5:2, 89-100
CrossRef246
Daniel M. Riche, Deborah S. Minor, Amber S. Holdiness, Honey E. East. (2009) An Issue of Dependence: Implications From the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) Trial. The Journal of Clinical Hypertension 11:2, 89-93
CrossRef247
Alan B. Weder. (2009) ONTARGET: How much RAS inhibition is enough?. Current Hypertension Reports 11:1, 7-9
CrossRef248
James A. Burton. (2009) Proposed three-letter abbreviations for homologues of the coded amino acids. Biopolymers 92:2, 132-136
CrossRef249
Fabrizio Montecucco, Aldo Pende, François Mach. (2009) The Renin-Angiotensin System Modulates Inflammatory Processes in Atherosclerosis: Evidence from Basic Research and Clinical Studies. Mediators of Inflammation 2009, 1-13
CrossRef250
Katherine R Tuttle. (2009) Could renin inhibition be the next step forward in the treatment of diabetic kidney disease?. Nature Clinical Practice Endocrinology & Metabolism 5:1, 20-21
CrossRef251
Y Semple, L Rankine. (2009) Aliskiren. Practical Diabetes International 26:1, 34-35
CrossRef252
Sharon Anderson, Radko Komers. (2009) Inhibition of the renin–angiotensin system: is more better?. Kidney International 75:1, 12-14
CrossRef253
Tae-Sun Ha. (2009) Diabetic Nephropathy in Childhood and Adolescence (II) ; Pathology and Pathophysiology. Journal of the Korean Society of Pediatric Nephrology 13:2, 99
CrossRef254
Pilar Mazón-Ramos, Alberto Cordero-Fort, Juan Quiles-Granado, Josep Guindo-Soldevila. (2009) Temas de actualidad en hipertensión arterial y diabetes. Revista Española de Cardiología 62, 14-27
CrossRef255
AH Jan Danser. (2009) (Pro)renin receptors: are they biologically relevant?. Current Opinion in Nephrology and Hypertension 18:1, 74-78
CrossRef256
Krishna K Gaddam, Suzanne Oparil. (2008) Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients?. Current Opinion in Internal Medicine 7:6, 606-612
CrossRef257
Steven A. Yarows, Suzanne Oparil, Samir Patel, Hui Fang, Jack Zhang. (2008) Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Advances in Therapy 25:12, 1288-1302
CrossRef258
Yan Chun Li. (2008) Vitamin D and diabetic nephropathy. Current Diabetes Reports 8:6, 464-469
CrossRef259
Shailendra Kapoor. (2008) Aliskiren: a rapidly, expanding role in the management of recalcitrant hypertension and renal disease. International Urology and Nephrology 40:4, 1115-1116
CrossRef260
Meda E. Pavkov, William C. Knowler, Robert L. Hanson, Robert G. Nelson. (2008) Diabetic nephropathy in American Indians, with a special emphasis on the pima Indians. Current Diabetes Reports 8:6, 486-493
CrossRef261
Ravi Nistala, Adam Whaley-Connell, James R. Sowers. (2008) Redox Control of Renal Function and Hypertension. Antioxidants & Redox Signaling 10:12, 2047-2089
CrossRef262
Kostas C. Siamopoulos, Rigas G. Kalaitzidis. (2008) Inhibition of the renin–angiotensin system and chronic kidney disease. International Urology and Nephrology 40:4, 1015-1025
CrossRef263
Guntram Schernthaner. (2008) Dual inhibition with losartan and aliskiren: a promising therapeutic option for type 2 diabetic nephropathy?. Nature Clinical Practice Nephrology 4:12, 656-657
CrossRef264
Sebastian Martini, Felix Eichinger, Viji Nair, Matthias Kretzler. (2008) Defining human diabetic nephropathy on the molecular level: Integration of transcriptomic profiles with biological knowledge. Reviews in Endocrine and Metabolic Disorders 9:4, 267-274
CrossRef265
Jack FM Wetzels. (2008) Renal outcomes in the ONTARGET study. The Lancet 372:9655, 2020
CrossRef266
Thomas R. Lux, Heinrich Taegtmeyer. (2008) Aliskiren combined with losartan: Thor’s hammer or Sigurd’s sword?. Current Hypertension Reports 10:6, 432-433
CrossRef267
Terry C. Major, Bronia Olszewski, Wendy Rosebury, Carlin Okerberg, Tage Carlson, Robert Ostroski, Richard Schroeder, Mark C. Kowala, Robert Leadley. (2008) A Nonpeptide, Piperidine Renin Inhibitor Provides Renal and Cardiac Protection in Double-Transgenic Mice Expressing Human Renin and Angiotensinogen Genes. Cardiovascular Drugs and Therapy 22:6, 469-478
CrossRef268
G. Schernthaner. (2008) Kidney disease in diabetology: lessons from 2008. Nephrology Dialysis Transplantation 24:2, 396-399
CrossRef269
Robert Weiss, Christopher A Graybill, Jennifer Linseman, Marshelle Warren. (2008) Inhibition of endothelin-1 with darusentan: a novel antihypertensive approach for the treatment of resistant hypertension. Therapy 5:6, 739-750
CrossRef270
Domenic A. Sica. (2008) Direct Renin Inhibition- Commonly Asked Questions. The Journal of Clinical Hypertension 10:11, 871-875
CrossRef271
Norberto Perico, Ariela Benigni, Giuseppe Remuzzi. (2008) Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nature Reviews Drug Discovery 7:11, 936-953
CrossRef272
Anne Katrin Sjølie, Ronald Klein, Massimo Porta, Trevor Orchard, John Fuller, Hans Henrik Parving, Rudy Bilous, Nish Chaturvedi. (2008) Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. The Lancet 372:9647, 1385-1393
CrossRef273
Monica Cortinovis, Dario Cattaneo, Norberto Perico, Giuseppe Remuzzi. (2008) Investigational drugs for diabetic nephropathy. Expert Opinion on Investigational Drugs 17:10, 1487-1500
CrossRef274
(2008) Aliskiren Combined with Losartan in Diabetes and Nephropathy. New England Journal of Medicine 359:10, 1068-1070
Full Text275
(2008) Journal Club. Kidney International 74:6, 691-692
CrossRef276
Philip R. Liebson. (2008) Diabetes Control and Cardiovascular Risk: ACCORD, ADVANCE, AVOID, and SANDS. Preventive Cardiology 11:4, 230-236
CrossRef277
Krishna K Gaddam, Suzanne Oparil. (2008) Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients?. Current Opinion in Nephrology and Hypertension 17:5, 484-490
CrossRef278
Matthias Barton. (2008) Reversal of proteinuric renal disease and the emerging role of endothelin. Nature Clinical Practice Nephrology 4:9, 490-501
CrossRef279
Haroonur Rashid. (2008) Direct renin inhibition: an evaluation of the safety and tolerability of aliskiren. Current Medical Research and Opinion 24:9, 2627-2637
CrossRef280
Jacyntha A. Sterling. (2008) Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy. Hospital Pharmacy 43:8, 676-683
CrossRef281
Roland E. Schmieder, Luis M. Ruilope. (2008) Blood Pressure Control in Patients With Comorbidities. The Journal of Clinical Hypertension 10:8, 624-631
CrossRef282
Ingelfinger, Julie R., . (2008) Aliskiren and Dual Therapy in Type 2 Diabetes Mellitus. New England Journal of Medicine 358:23, 2503-2505
Full Text
- Letters
